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PART 1  
BACKGROUND 
This chapter introduces the necessary background information relevant for this 
thesis. Here biomembranes, membrane-active peptides, fluorine-labelled amino acids 
and solid state 19F-NMR are described to present the concepts and to introduce the 
terminology used within the thesis. The chapter also presents the motivation of this 
work with regard to the biological problem of membrane-peptide structural analysis. 
 
 
1.1. Biological membranes and membrane-active peptides 
1.1.1. Biological membranes 
 
All cells of all living organisms are enveloped by a membrane, which serves as 
a boundary between the cell interior and the extracellular environment.1,2,3 
Functionally the membranes do not only protect the cell from mechanical and 
chemical influences, but they also control transport (selective and non-selective), 
receive and transduce extra-cellular signals, initiate informational cascades, provide a  
specific environment for enzymatic catalysis, regulate recognition, adhesion and 
communication with other cells, provide an anchor for the extra- and intra-cellular 
skeleton, etc.4 The same kinds of membranes enclose organelles of eukaryotic cells 
presenting a similar range of functions. 
Biological membranes mainly consist of lipids and proteins. Minor constituents 
like water, various inorganic ions, small organic molecules and carbohydrates are 
also present, but up to few percent of total weight only. Therefore, lipids and proteins 
determine all the membrane functions. Protein/lipid ratios can vary greatly for 
membranes of different origins. The protein content can be as low as 20% of the 
membrane dry weight (neuronal cells), or as high as 78% (Bacillus megaterium).5  
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Fig. 1.1. “Fluid-mosaic“ model of an eukaryotic cell membrane according to Singer and Nicholson.6,7 
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The current understanding of biomembrane architecture is described by a 
model proposed in 1972 by Singer and Nicholson - the “fluid-mosaic” model (Fig. 
1.1).6,7 It considers a membrane as a lipid bilayer forming a two-dimensional fluid, in 
which the other embedded components (proteins) are freely diffusing.  
The lipid composition of a membrane can differ a lot depending on the 
membrane origin.8 The most abundant lipid classes are phospholipids, glycolipids and 
steroids (Fig. 1.2).9  A phospholipid molecule consists of a lipophilic side chain 
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Fig. 1.2. Typical membrane lipids.5,8 Abbreviations: PS - phosphotidylserine; PE - phosphotidylethanolamine; PC - 
phosphotidylcholine; PI - phosphotidylinositol, SM - sphingomyelin. The residues of phosphoric acid are highlighted in 
red, of glycerol - in green, of glucose - in yellow, of sphingosine - in blue. 
 
(“tail”), glycerol residue (“neck”) and a polar hydrophilic moiety (“head”). Being 
arranged linearly, “tail” - “neck” - “head”, phospholipids possess an overall 
amphiphilic character. In an environment of uniform dielectric properties (e.g. in 
water) they tend, therefore, to assemble into aggregates, where energetically 
unfavorable contacts are minimized. The ratio between the molecular cross-sectional 
areas of a head group and its tail determines the overall shape of the molecule, which, 
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in turn, influences the molecular shape of the self-assembled aggregate.10 In aqueous 
solution, most membrane phospholipids tend to form a lamellar phase, in which the 
lipid chains make up the hydrophobic core, while the headgroups are forming the 
interface towards the polar aqueous environment.11 
 
1.1.2. Membrane-active peptides 
 
There are many natural and synthetic peptides known, which can interact with 
membranes. For instance, opioid peptides ([Leu], [Met]-encephalins, dynorphin A), 
mastoparan X, substance P, glucagon, neurotensin, penetratin and many others.12,13,14 
Membrane-active peptides are very diverse functionally: they can demonstrate 
antimicrobial, cell-penetrating, fusogenic, amyloidogenic, signalling, anticancer, or 
immunomodulating activities, among others. In this work several peptides are used, 
which represent two important types of such functional interactions: antimicrobial 
peptides (AMPs) disrupt bacterial membranes, and cell-penetrating peptides (CPPs) 
can translocate across membranes. 
 
1.1.2.1. Antimicrobial peptides 
 
AMPs are a group of peptides, which inhibit growth of microorganisms. These 
peptides are found in various living organisms and are supposed to be part of their 
innate immune system (Table 1.1).15-18161718Also many synthetic sequences and 
peptidomimetics show similar inhibitory effects, and therefore belong to the same 
functional group. Obviously, by functional definition, AMPs are antibiotics. They 
are active against rather wide classes of targets; among those are Gram-positive and 
Gram-negative bacteria, enveloped viruses, fungi, protozoa. More than 800 such 
peptides are reported to date.19 
 
Тable 1.1. Some naturally occurring AMPs.16,18 
 
peptide amino acid sequence origin 
magainin 2 GIGKFLHSAKKFGKAFVGEIMNS frog 
LL37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES human 
bactenecin 1 RLC1RIVVIRVC1R cow 
apidaecin GNNRPVYIPQPRPPHPRI bee 
androctonin RSVC1RQIKIC2RRRGGC2YYKC1TNRPY scorpion 
protegrin 1 RGGRLC1YC2RRRFC2VC1VGR-NH2* pig 
*Cycteins, which are connected by a disulfide bond are denoted by the corresponding index (С1, С2). 
 
A uniform classification of AMPs does not exist due to the huge versatility of 
the group. Most often, using structural criteria, they are divided into the following 
classes: a) linear α-helical peptides (e.g. magainin 2, pardaxin); b) cyclic and small 
proteins forming β-sheets (e.g. gramicidin S, polymixin B); c) peptides, rich in one 
or more specific natural amino acid (e.g. histatin, indolicidin); d) cyclic peptides 
with thio-ether rings (e.g. lantibiotics); e) peptaibols containing the unusual amino 
acid Aib (e.g. alamethicin); f) macrocyclic peptides, which contain cysteine (e.g. 
  
7
circulins).20 However, all AMPs are generally agreed to have some common 
features:21 
1. short length: 10-50 amino acids; 
2. overall cationic character; 
3. primary or secondary amphipathic structure, which may be gained e.g. upon 
interaction with lipid membranes. 
In contrast to conventional antibiotics, AMPs are often speculated to kill 
microorganisms by disruption of their biomembrane, and for many of them an action 
via receptor-independent mechanisms has been demonstrated.22 Some models of 
membrane  permeabilization  by AMPs  are  shown in Fig. 1.3. In the “carpet” model, 
 
 
 
Fig. 1.3. Some postulated models of membrane permeabilization by antimicrobial peptides: a) “carpet” model; b) 
“barrel-stave” model; c) “worm-hole” model.21,22 
 
the peptides are aligned on the outer leaflet parallel to the membrane surface and 
thereby induce non-specific rupture of the lipid bilayer. In the “barrel-stave” model, 
on the contrary, the peptides upon binding to the membrane surface arrange into 
aggregates and form transmembrane pores. The “worm-hole” model is similar to the 
“barrel-stave”, but here lipids are intercalated with peptides to line up the pore.  
Since AMPs act via receptor-independent pathways, it is believed, that, on the 
contrary to conventional antibiotics, bacteria are not able to develop a resistance 
against them. Therefore, AMPs are supposed to be promising candidates as a novel 
generation of antibiotics.23,24 Hence, any information concerning mechanisms of 
action of AMPs (e.g. their conformation, alignment and dynamics in biomembranes) 
is of exceptional importance. 
 
1.1.2.2. Cell-penetrating peptides 
 
CPPs are a group of short peptide sequences (normally up to 40 amino acids) 
with the ability to gain access to the cell interior by means of different mechanisms 
and with the capacity to promote the intracellular delivery of covalently or non-
covalently conjugated bioactive cargos.25-3226272829303132 
A strict classification of CPPs does not exist because of their vast variety. 
According to the origin, all CPPs can be roughly divided into two groups: natural 
(segments of natural proteins) and designer-made peptides (Table 1.2). Structurally, 
C 
A B
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CPPs are either entirely basic, or cationic and amphipathic.33,34,35 Also, CPPs are 
shown to promote the intracellular delivery of different covalently or non-covalently 
attached cargoes, like DNA, RNA, peptides, proteins, liposomes, fullerenes, 
etc.36,37,38 
 
Table 1.2. Some known CPPs.32,39 
 
peptide amino acid sequence origin 
Tat(48-60) GRKKRRQRRRPPQ human 
pAntp(43-58) RQIKIWFQNRRMKWKK fly 
pVEC LLIILRRRIRKQAHAHSK VE cadherin 
MAP KLALKLALKALKAALKLA-NH2 designed peptide 
(Arg)8 RRRRRRRR designed peptide 
MPG GALFLGFLGAAGSTMGAWSQPKKKRKV designed peptide 
transportan GWTLNSAGYLLGKINLKALAALAKISIL-NH2 designed peptide 
 
The physical and chemical features of CPPs are similar to those of AMPs 
(amphipatic or/and cationic character, short length), but on the contrary to the latter 
group, CPPs have to be non-toxic compounds.  
So far, no clear understanding concerning the mechanism of internalization of 
CPPs exists.39 Until 2003 only energetically independent mechanisms were 
speculated to be involved. At the moment, however, it is believed that both non-
endocytotic (energy-independent) and endocytotic (energy-dependent) pathways can 
take place. It also appears, given the complex nature of the CPP`s target - the whole 
cell- that different mechanisms can be used simultaneously.40 The issue is even more 
complicated in view of recent fundings, that the prevailing mechanism of cell-
penetration is highly dependent on the target cell line and the nature of the cargo.40 
Anyway, even when purely endocytotic internalization is taking place, escape from 
the endosome and transport across the lipid bilayer has to take place in order to reach 
the cytosol. Examples of mechanistic models of this essential step are outlined in 
Fig. 1.4. 
 
 
 
Fig. 1.4. Some postulated mechanisms for the translocation of CPPs through the lipid bilayer: a) “inverted micelle” 
model; b) “barrel-stave” model; c) “worm-hole” model.27 
 
Since CPPs could be used as transport systems for the delivery of drugs, 
nanoparticles (e.g. magnetic nanoparticles) or fluorescent labels (e.g. quantum dots) 
C 
A B
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into a cell,37,39,40 new technologies of chemical and/or physical manipulation of cells 
based on the application of CPPs are expected to emerge in the near future. 
Therefore, better insight into the mechanisms of action of CPPs, in particular their 
structure upon binding to membranes, is of great practical importance. 
 
 
1.2. Methods of structural characterization of peptides 
All methods for structural characterization of peptides can be roughly divided 
into those providing either partial or full structural information. The first group - for 
example, electron paramagnetic resonance, neutron diffraction, circular dichroism, 
fluorescence, or IR-spectroscopy41,42 - is used mainly for the overall characterization 
of peptide structure. The direct methods, such as NMR in solution,43 X-ray 
analysis44,45 or electron microscopy (EM)46 are, on the contrary, capable to establish 
fully resolved 3D peptide structures. All the latter methods, however, are not well 
suited to study membrane-active peptides. This is because the conformation of a 
peptide under the conditions imposed by the respective method (e.g. in solution, 
crystal, or on EM grid) and in the native environment can differ a lot. Therefore the 
structures determined this way, although highly accurate, may be biologically 
irrelevant. In the case of X-ray analysis and EM, an additional problem is due to the 
difficulty of getting suitable crystals (3D or 2D respectively) of peptide-membrane 
complexes. One of the few techniques able to resolve three-dimensional structural 
details of membrane-associated peptides in their quasi-native state is solid state 
NMR-spectroscopy.47,48 
 
1.2.1. Peptide secondary structure 
  
Since peptides are relatively small compounds, their spatial conformation is 
generally described in terms of secondary structure (on the contrary to proteins, 
which possess a more complex architecture). The secondary structure of peptides and 
proteins can be described by the torsion angles ϕ, ψ and ω (Fig. 1.5). 
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Fig. 1.5. Definition of torsion angles ϕ, ψ, ω in peptides. 
 
Based on the large body of structural data for peptides and proteins, and on the 
computational calculations, the typical (averaged) values of ϕ, ψ, ω for common 
secondary structures are known (Table. 1.3).49,50 
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Table 1.3. Typical values of ϕ, ψ, ω for the most common structures of polypeptide backbone. 
 
secondary structure element ϕ (°) ψ (°) ω (°) 
310-helix -60 -30 +180 
α-helix -57 -47 +180 
π-helix -55 -76 +180 
polyproline helix:    
type I (PP I)  -83 +158 0 
type II (PP II) -76 +146 +180 
parallel β-sheet -119 +113 - 
antiparallel β-sheet -139 +135 - 
β-turns* ϕi+1 (°) ϕi+1 (°) ϕi+2 (°) 
type I -60 -30 -90 
type I' +60 +30 +90 
*According to the definition, β-turn consists of four amino acid residues. The numeration begins at the N-terminus from 
residue i- to i+3. Indexes at the torsion angles are shown in agreement with this numeration. 
 
 
1.2.1. Circular dichroism spectroscopy 
 
Circular dichroism (CD) spectroscopy is a form of the optical spectroscopy that 
measures the difference in absorbance of right- and left-circularly polarized light by 
an optically active substance. It is extensively applied to the structural 
characterization of peptides and proteins.51,52,53 Fig. 1.6 illustrates the characteristic 
CD spectra of some common peptide/protein secondary structures.54 
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Fig. 1.6. CD spectra corresponding to a conformation of a) α-helix, antiparallel ß-sheet; b) polyproline type I (PP I), 
polyproline type II helix (PP II) and random coil.54 
 
Normally CD spectra are measured between 260 and approximately 180 nm. If 
the peptide adopts more than one conformation, it is possible to extract the content of 
each secondary structure element (by numerical deconvolution of the CD spectrum). 
However, for quantification, CD data at low wavelengths (175-190 nm) are the most 
  
11
critical, and given the overlap with absorbances of common solutes (salts, buffers, 
lipids), collection of these data can be very difficult. 
 
1.2.2. Solid state 19F-NMR 
 
In contrast to the situation of globular proteins in solution, membrane-bound 
peptides are motionally restricted in the lipid bilayer, which gives rise to anisotropic 
(i.e. orientation dependent) NMR parameters. Today a number of methods have been 
established to use anisotropic interactions as a source of structural information by 
solid state NMR. Such studies of peptides or proteins typically rely on the use of 
isotope labels (2H, 19F, 15N, 13C) that are either uniformly or selectively introduced 
into the system of interest.55 These labels are used to measure structural and 
orientational constraints (e.g. chemical shift anisotropy (CSA), dipole-dipole, or 
quadrupole interactions).56,57 The restraints measured on several individual labels are 
combined to yield the structure as well as orientation of the whole polypeptide 
molecule when bound to the membrane. 
 
 
1.2.2.1. 19F nucleus in NMR 
 
The 19F nucleus is an almost ideal NMR label for the following reasons: 
1. similarity with 1H in the van der Waals radii makes substitution of 1H/19F rather 
safe in terms of steric parameters; 
2. on the contrary to 1H, 2H, 13C, 31P and 15N, fluorine is almost absent in biological 
systems, thus having no natural abundance background; 
3. fluorine possesses one natural isotope (19F) with the spin І = ½, which is relatively 
simple to measure, since only CSA and dipole-dipole couplings (but not quadrupole 
interactions) are present for this nucleus; 
4. being second only after 1H (and radioactive 3H), 19F possesses the highest 
gyromagnetic ratio γ amongst all other isotopes in the periodic table, providing it 
with an exceptional NMR sensivity (Table 1.4);58,59 
5. the broad range of chemical shifts (~500 ppm) of 19F allows much better resolution 
of the signals compared with 1H; 
6. fluorine has a high sensivity of chemical shift towards concentration, temperature, 
pH, etc. 
 
Table 1.4. Physical properties of 19F in comparison with other biologically relevant NMR-active isotopes. 
 
isotope 1Н 2Н 13С 15N 19F 31P 
electronegativity (Poling) 2.1 2.1 2.5 3.0 4.0 2.1 
van der Waals radius (nm) 0.12 0.12 0.17 0.15 0.13 0.19 
spin I ½ 1 ½ ½ ½ ½ 
gyromagnetic ratio γ/2π (MHz/Т) 42.58 6.53 10.70 4.31 40.03 17.23 
sensivity (%) ~I(I+1) γ3 100 0.96 1.59 0.10 83.3 6.63 
natural abundance (%)  99.985 0.015 1.1 3.7 100 100 
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One should always remember, however, that due to substantial differences in 
electronegativity (Table 1.4), 19F/1H replacement can alter properties of the 
compound under study.60,61,62 Also, technically the measurement of 19F is quite 
demanding, since it is not trivial to separate the 19F frequencies from that of 1H that is 
close by.  
 
 
1.2.2.2. Methodology of membrane-peptide structural studies by solid state 19F-
NMR 
 
The orientation, conformation and dynamics of membrane-bound peptides can 
be determined using the strategy depicted in Scheme 1.1.58 
 
 
 
Scheme. 1.1. General tactics to determine peptide orientation, conformation and dynamics in lipid bilayers by solid 
state 19F-NMR. 
 
1. 19F-labelled peptide analogues are normally obtained by solid phase peptide 
synthesis (SPPS) replacing a natural amino acid by a 19F-labelled one.  
2. In order to check whether 19F-labelling affects the properties of the peptide 
under study, the quasi-native structural (e.g. by CD, IR or NMR in solution) and 
functional properties (e.g. antimicrobial activity for AMPs, cell-penetration for 
CPPs, fusion activity for fusogenic peptides, etc.) of the 19F-labelled analogues have 
to be assayed and compared to the respective behaviour of the parent peptide (wild 
type peptide). For further studies only those 19F-labelled analogues are used, which 
have characteristics similar/identical to those of the wild type peptide.  
3. To provide a membrane environment, the 19F-labelled analogues are 
reconstituted into the relevant mixture of lipids, where the lipid bilayers are 
uniaxially aligned on glass plates (oriented flat membranes). In most cases the 
unique orientation is assumed by the 19F-labelled peptides as well. 
4. The peptide-lipid samples are then measured by solid state 19F-NMR 
spectroscopy. If the peptide is labelled with a single F-substituent, then the 
anisotropic chemical shift of fluorine is used for structural calculations. However, 
since the fluorine chemical shift is rather difficult to determine precisely,63 the 
synthesis of 19F-labelled peptide analogues
structural and functional assays to 
characterize the 19F-labelled analogues
reconstitution into oriented lipid bilayers 
solid state 19F-NMR spectroscopy 
calculation of the structural parameters 
1. 
2. 
3. 
4. 
5. 
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method based on the analysis of dipole-dipole couplings in CF3-groups is more 
promising.58 One more advantage of CF3-group over single F-substituent lies in its 
threefold higher signal intensity. 
5. The dipolar coupling of a rotating CF3-group depends on the angle θ between 
the СF3 axis and the В0 (Fig. 1.7):64 
∆CF3(θ) = ∆0CF3 <3cos2θ-1>/2 
 
 
 
Fig. 1.7. 19F-NMR spectrum of an uniaxially aligned СF3-group at different orientations with respect to the static 
magnetic field В0. Changing the angle (θ) between the C-CF3 vector and B0 influences the dipole-dipole coupling in the 
СF3-group. 
 
Therefore, by measuring ∆CF3 it is possible to calculate the orientation of a CF3-
group with respect to В0 (θ). If the CF3-group is rigidly attached to the molecular 
framework, the orientation of the whole labelled segment can be obtained as well. 
The information from several individual CF3-labels is thus used to calculate the 
structure as well as the orientation of the whole peptide. 
An orientation of a peptide of a defined conformation in a lipid bilayer can be 
described by 3 parameters: ρ, τ and Smol (Fig. 1.8).65 
 
 
Fig. 1.8. Hypothetical helical peptide in an aligned lipid bilayer. Orientational parameters: τ - angle between peptide 
axis z and membrane normal N; ρ - angle, which describes the azimuthal rotation of the helix around axis z; Smol - 
parameter, which characterizes the mobility of the peptide as an “isotropic-wobble”. 
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To calculate these three parameters one must use the data from at least four 
individual labels.  
 
 
1.3. 19F-NMR labels in solid state 19F-NMR 
 
In this work the terms “19F-NMR label” or “19F-label” mean a specifically 
fluorinated amino acid, which has been or may potentially be used in peptide 
structural studies by solid state 19F-NMR. 
 
1.3.1. Known 19F-NMR labels, their advantages and drawbacks 
 
Even though a wealth of fluorine-labelled amino acids (FAAs) have been 
reported so far,66,67,68 only few of them have been used as 19F-NMR labels (Fig. 1.9). 
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χ2
χ1
χ2
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Fig. 1.9. Fluorine-labelled amino acids, which have been used as 19F-labels. 
 
This is because not every FFA can be applied for this purpose. To be a proper 19F-
NMR label, fluorine-labelled amino acid must meet several criteria:  
1. the amino acid has to be conformationally rigid/restricted to place the 19F-reporter 
group (CF3 or single-F) in a well-defined position with regard to the peptide 
backbone; 
2. being in place of a natural amino acid, the 19F-label must not disturb the structural 
and functional characteristics of the peptide; 
3. the 19F-label must be chemically stable, and the amino- and carboxy-groups must 
be sufficiently reactive to be easily incorporated into the peptide by standard methods 
of SPPS; 
4. the FFA possessing a CF3-group is more promising than the corresponding 
analogue having a single F-substituent (Chapter 1.2.2.2). 
The compatibility of the known 19F-NMR labels 1-7 with the abovementioned 
criteria is given below: 
169,70,71 and 272,73,74 closely resemble the structures of Trp and Phe and are often 
used to substitute these natural amino acids in peptides. However, the position of the 
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fluorine atom in both 1 and 2 depends on the angles χ1 and χ2, which makes a 
structural interpretation of the NMR parameters ambiguous.  
375-78767778and 4,79,80,81 being derivatives of phenylglycine, have been successfully 
used to substitute Ala, Val, Leu and Ile in peptides. In these labels the position of the 
19F reporter group is well-defined, but analysis of the chemical shift anisotropy of the 
single 19F-substituent in 3 must still take into account the value of χ1. In contrast, fast 
rotation of the CF3 group in 4 renders all 19F interactions axially symmetric and 
collinear with the Cα-Cß bond, which makes this amino acid ideal for orientational 
analysis. The major disadvantage of this 19F-NMR label, however, relies on its 
propensity to racemize during peptide synthesis. Thus, the target peptides, being a 
mixture of epimers, must be separated by HPLC, which is not always feasible.82 One 
must always remember as well that the benzene ring is known to participate in 
diverse types of “weak” interactions,83 hence the replacement of Ala, Val, Leu, Ile by 
3 or 4 may change the properties of the peptide under investigation.84  
Both 585,86,87 and 688,89 are structural analogues of Ala. Even though 19F-label 5 
has been successfully used in peptide studies, its use to obtain orientational 
constraints is restricted, because the position of the F-reporter depends on χ1. Amino 
acid 6, on the contrary, has no such deficiency, since the axially symmetric CF3-
group is directly attached to the aminocarboxylate moiety. However, the high 
propensity of its derivatives to eliminate HF under basic conditions78,90 renders an 
application of 6 as 19F-label less suitable.91  
Compound 7 is an analogue of the unusual natural amino acid Аib 
(8). The CF3-group in 7 is directly attached to Cα, and therefore its 
position is fixed. Moreover, 7, in contrast to 6, is stable under both acidic 
and basic conditions and due to the absence of proton at Cα it does not 
racemize. This makes 7 an ideal 19F-label to study Aib-rich peptides.92,93 However, 
since the amino group is sterically hindered and electron deficient as well (due to the 
influence of the bulky electronegative СF3-group), an incorporation of 7 into peptides 
requires very long coupling times and can not be achieved by standard protocols of 
SPPS.94,95 
From the considerations given above it is clear that all of the known 19F-labels 
1-7, despite their use in peptide structural analysis, have significant disadvantages.  
 
1.3.2. Known mono-CF3-substituted analogues of Ala, Val, Leu, Ile, Met and 
Pro as potential 19F-NMR labels 
 
 In order to find proper 19F-NMR labels among the already known fluorine-
labelled amino acids, it makes sense to consider only those compounds, which  
1. resemble the structures of natural amino acids to be substituted non-perturbingly; 
2. possess single-CF3-substitution.  
Let us first look into the analogues of Ala, Val, Leu, Ile, Met. A selection of 
candidates which resemble the structures of these amino acids is intuitive and is 
prevented by the absence of a strict definition of the term “structural relation”. Fig. 
1.10 depicts all such CF3-substituted α-amino acids with a primary amino group, 
NH2
COOH
8
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which possess saturated side chains of 2-6 carbon atoms (9-17). Amino acids 
containing another atom types in the side chain were excluded from the search, 
except for those having sulfur (to mimic Met).  
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Fig. 1.10. Known mono-СF3-substituted analogues (9-17) of Ala, Val, Leu, Ile, Met (14c is known as a mixture of 
epimers; for 11b, 12, 14d, 14e both epimers are described). Symbols Cn (n = 2, 6) correspond to the number of carbon 
atoms in the side chain.96-113 
 
The flexible nature of the CF3-group in candidates 9,96,97,98 10,99 11b,100,101,102 
11c,98 13a,103 13b,104 14c,105 14d,106,107 14e,108,109,110 14f,111 1599 rules out their use as 
19F-labels. Compounds 11a,112,113 12,114 14a,115 14b,112,113 16a112,113 and 16b112,113 have 
no such deficiency, as the CF3-group is attached to Cα (or to Cß of the rigid 
cyclopropane ring in 12). Still, the presence of the bulky electron-withdrawing CF3-
group in close spatial proximity to the aminocarboxylate part could severely alter the 
steric and electronic environment of the peptide backbone. It will also reduce the 
chemical reactivity of the amino acids, thereby making their use in SPPS difficult. 
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In the case of Pro, it is worth to consider the mono-CF3-substituted analogues 
of proline and its nearest structural homologues - pipecolic and azetidine acids. 
Amino acids possessing atoms other than carbon in the side chain were not 
considered here. Amongst the wealth of theoretically possible variants, only 
compounds 17(a,b)116-119117118119and 18120 are described in the literature (Fig. 1.11). 
 
N
H
COOH
CF3
N
H
COOH
CF3
N
H
CF3 COOH
 
17a 17b 18  
 
Fig. 1.11. Known mono-СF3-substituted analogues of Pro, pipecolic and azetidine acid (17-18).116-120 
 
Amino acids 17(a,b) resemble the structure of Pro very closely. Moreover, the 
conformational mobility of the pyrrolidine ring in 17(a,b) might be substantially 
reduced by the “pucker effect” of the bulky electronegative CF3-group.121 However, 
since the position of the CF3-group is not rigidly fixed, isomers 17(a,b) are not 
suitable as 19F-labels. In the CF3-substituted derivative of azetidine 
acid, compound 18, the conformation of the side chain, and 
therefore the location of CF3-group, is highly restricted by the 
four-membered ring. Still, the presence of the bulky electron-
withdrawing CF3-moiety in the spatial proximity to the aminocarboxylate part will 
diminish the chemical reactivity of the amino acid and can influence the peptide 
conformation.92-95 Moreover, this compound is only known in the Boc-protected form 
(19). Therefore, amino acid 18 cannot be considered as a proper 19F-label.  
N
CF3 COOH
19Boc
  
18
PART 2  
AIMS OF THE WORK 
  
The aims of this dissertation were as follows: 
 
- Design and synthesis of an optimized 19F-NMR label (label 1) as a 
substituent for non-polar aliphatic amino acids (Ala, Val, Leu, Ile, Met) 
for solid state NMR structural studies of membrane-active peptides. 
 
- Design and synthesis of further structural 19F-NMR labels (labels 2) as 
potential substituents for proline in biologically active peptides. 
 
- Incorporation of label 1 into the structurally and functionally well 
characterized animicrobial peptides GS (gramicidin S) and PGLa 
(peptidyl-glycylleucine-carboxyamide), to check of the compatibility of 
label 1 with solid state pepide synthesis (SPPS). 
 
- Study of the 19F-labelled analogues of GS and PGLa by established 
functional (antimicrobial assays) and structural (circular dichroism) 
methods in order to confirm the compatibility of label 1 with the 
structure and function of these peptides. 
 
- Proof-of-principle solid state 19F-NMR studies utilizing the novel label 
1 on PGLa and GS. 
 
- Incorporation of the new labels (labels 1 and 2) into the novel cell-
penetrating peptide SAP (Sweet Arrow Peptide) to check the 
compatibility of label 2 with SPPS, and to examine any possible 
influence of label 2 (when substituted for Pro) on the conformation of 
SAP. 
 
- Combined use of labels 1 and 2 to study the structure and orientation of 
SAP in lipid bilayers by solid state 19F-NMR analysis. 
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PART 3 
NEW 19F-NMR LABEL FOR SUBSTITUTION OF NATURAL NON-POLAR 
ALIPHATIC AMINO ACIDS (ALA, VAL, LEU, ILE, MET) IN PEPTIDES:  
(S)-3-(TRIFLUOROMETHYL)-BICYCLOPENT-[1.1.1]-1-YLGLYCINE          
(CF3-BPG) 
 
This chapter describes the stereoselective synthesis of the novel CF3-
substituted conformationally rigid amino acid (S)-3-(trifluoromethyl)-bicyclopent-
[1.1.1]-1-ylglycine (CF3-Bpg). The compound was designed as a proper 19F-NMR 
label for substitution of Ala, Val, Leu, Ile and Met in membrane-bound peptides. 
The results described in this chapter have been recently published in 
Mykhailiuk P. K., Afonin S., Chernega A. N., Rusanov E. B., Platonov M. O., 
Dubinina G. G., Berditsch M., Ulrich A. S., Komarov I. V. Conformationally rigid 
trifluoromethyl-substituted α-amino acid designed for peptide structure analysis by 
solid state 19F-NMR spectroscopy // Angew. Chem. - 2006. - Vol. 118. - P. 5787-
5789; Angew. Chem. Int. Ed. - 2006. - Vol. 45. - P. 5659-5661. 
 
 
3.1. Design of the target structure 
 
The principles of design were based on the known advantages and 
disadvantages of the previously used 19F-labels (Chapter 1.3.2). In search of a rigid L-
amino acid that would fulfil all criteria for a proper 19F-label, the bicyclo-
[1.1.1]pentane system was chosen. Placing the CF3 and aminocarboxylate moieties at 
the bridgehead positions of this skeleton yields the 19F-labelled amino acid 20 (CF3-
Bpg) as the target (Fig. 3.1). The Cα-Cß and C-CF3 bonds in 20 are collinear; the side 
chain can rotate only around these bonds. In contrast to 3 and 4, in 20 the CF3 group 
and the Cα are separated by a saturated bicyclic cage. This should make 20 less prone 
to racemization, since the transmission of electronic effects across the bicyclo-
[1.1.1]pentane cage is far less pronounced than through an aromatic ring.122 Neither 
degradation by the loss of HF (as in 6) nor an unusually low reactivity of the 
aminocarboxylate moiety as a result of steric hindrance (as in 7) are expected for 20 
under SPPS conditions. 
 
COOH
NH2
F3C F3C
COOH
NH2
NH2
COOH
CF3
F3C
CH3 NH2
COOHCOOH
NH2
F
4 (4CF3-Phg) 6 (F3-Ala)
20 (CF3-Bpg)
7 (F3-Aib)3 (4F-Phg)
 
 
Fig. 3.1. Known (3, 4, 6, 7) and proposed (20) 19F-labels. 
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To examine the suitability of 20 for substitution of non-polar amino acids, its 
calculated properties123 were compared with those of the non-polar proteinogenic 
amino acids and the aforementioned 19F-labels 3, 4, 6, 7 (Table 3.1). The shape and 
steric volume of 20 resemble closely the corresponding values of Leu, Ile, Met, Trp, 
and Phe. The similarity to Pro, Val, and Ala is poorer. The non-aromatic character of 
20 constitutes its main difference to Trp and Phe. If one considers the values of 
octanol/water partition coefficients, a substitution of Leu, Ile, or Met by 20 would 
cause minimal changes in the mean hydrophobicity, which is an important 
prerequisite for the proper folding of a polypeptide.124 According to all parameters 
from Table 3.1. 20 is closer to the natural non-polar amino acids than any of the 
previously used phenylglycine derivatives (3, 4). 
 
Table 3.1. Calculated physical properties of 19F-labels 3, 4, 6, 7, 20 and natural amino acids Met, Ile, Leu, Val, Ala, Pro, 
Phe, Trp.123 
 
molecule SASA [Ǻ2]а FOSA [Ǻ2]b volume [Ǻ3]c QlogPo/wd 
CF3-Bpg(20) 384.8 136.2 624.9 - 0.72 
4F-Phg (3) 359.7 15.6 561.4 -1.73 
4CF3-Phg (4) 405.3 15.7 647.0 -0.53 
F3-Ala (6) 276.9 20.1 407.7 -2.0 
F3-Aib (7) 301.3 69.4 454.1 -1.73 
Met 357.8 167.4 549.5 -1.63 
Ile 338.6 204.5 527.5 -1.65 
Leu 334.5 205.7 522.9 -1.64 
Val 311.8 176.1 474.0 -1.96 
Ala 260.8 105.3 368.5 -2.63 
Pro 301.6 175.8 449.0 -2.04 
Phe 364.9 60.7 592.3 -1.06 
Trp 416.3 43.3 683.8 -0.92 
а) solvent-accessible surface area; b) hydrophobic component of SASA; с) total solvent accessible volume; d) predicted 
octanol/water partition coefficient. 
 
 
3.2. Planning the synthesis of CF3-Bpg 
 
 Retrosynthetic analysis of 20 was based on a comparison with synthetic 
approaches to amino acids with similar structure. At the time this work was started, 
there were two such compounds described in the literature: 21125 and 22126 (Fig. 3.2).  
 
NH2
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N N
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Fig. 3.2. Known amino acids with the bicyclopent-[1.1.1]-1-yl skeleton.125-126  
 
The key  step  in the synthesis of both 21 and 22 is the asymmetric Strecker reaction 
of aldehydes obtained from propellane 23 (Scheme 3.1). 
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Scheme 3.1. Known syntheses of 21 and 22 (R* - chiral auxiliary).125-126 
 
The transformations depicted above were taken as a basis for the retrosynthetic 
analysis of 20 (Scheme 3.2). 
 
CF3
O
HNH2
COOH
CF3
2320  
 
Scheme 3.2. Retrosynthetic scheme of 20. 
 
 
3.3. Synthesis of CF3-Bpg and proof of its absolute configuration 
 
The proposed strategy was successfully realized (Scheme 3.3). 
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Scheme 3.3. Synthesis of 20. Reagents and conditions: a) 40% aq. NaOH, CHBr3; b) MeLi, pentane, -78 ºC, 0.5 h; c) 
CF3I, pentane, RT, 20 h; d) t-BuLi, Et2O, -78 ºC, 1 h; e) HCO2Me, Et2O, -78 ºC, RT, 3 h; f) (R)-α-phenylglycinol, 
CH2Cl2, RT, 2 h; g) Me3SiCN, RT, 10 h; h) chromatographic separation; i) MeOH, reflux, 3 h; j) Pb(OAc)4, CH2Cl2, 0 
ºC, 5 min; k) 20% HCl, reflux, 2 h; l) chromatography on Dowex-50. 
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The first three synthetic steps were performed according to literature 
procedures. Dibromocyclopropanation of dichloroisobutene 24127 over NaOH/CHBr3 
gave the corresponding dibromocyclopropane 25. The key intermediate of the whole 
synthesis - propellane 23128-132129130131132- was obtained by treating 25 with MeLi. Addition of 
CF3I at the “inverted” carbon atoms of propellane led to iodide 26. According to the 
literature procedure, iodide 26 must be purified by crystallization, which leads to a 
loss of material.133 Here, however, crude 26 was obtained with a purity of › 95% and 
therefore no purification was needed at all (yield 62% calculated on 25).  
The incorporation of the -CHO moiety into the bicyclopentyl skeleton was 
inspired by an analogous formylation of 1-norbornyllithium 32 to produce aldehyde 
33 (Scheme 3.4).134  Similarly,  iodide  26 was converted to the corresponding lithium 
 
Li CHO OH
(up to 79%)
32
1) DMF
2) water
34
+
(up to 50%)
33
 
 
Scheme 3.4. The known synthesis of 33. Depending on the reaction conditions the side product 34 formed in 0-50% 
yield. The highest yield of 33 was 79%.124 
 
salt by reaction with t-BuLi, and treated afterwards with an excess of formylating 
reagent. Taking into account an expected high volatility of 
27, DMF (b.p. = 154 ºС) was replaced by the more volatile 
HCO2Me (b.p. = 31 ºС). To inhibit formation of side 
product 35, the reaction was carried out at -78 ºС. 
Surprisingly, together with the target aldehyde 27, the 
hemiacetal 28 formed as well. The ratio 27/28 in the mixture was ~2/1. As expected, 
after addition of excess of MeOH to 27/28, in both 1Н- and 19F-NMR spectra the 
signals of 27 disappeared, while the signals of 28 remained (Scheme 3.5). 
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Scheme 3.5. Conversion of aldehyde 27 into hemiacetal 28 by dissolving in MeOH.  
 
The formation of 28 in the synthesis of 27 is a quite unexpected observation, 
since acyclic aliphatic hemiacetals without electron-
withdrawing substituents in direct proximity to the carbonyl 
group are supposed to be unstable.135 On the other hand, 
while the standard values of the 4J(H, H)-constants are in a 
range of 0-3 Hz,136 the 4J(H, H) between the bridgehead protons in the 
bicyclo[1.1.1]pentane skeleton is known to be as high as 18 Hz.137 This suggests the 
H H
4J(H, H) = 18 Hz
CF3
OH
CF335
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transmission of electronic effects across the bicyclopentane cage to be efficient, 
which may stabilize 28 via the electron-withdrawing effect of the CF3-group. 
Assuming the transformation acetal ↔ aldehyde to be reversible,135 the 
unseparated mixture 27/28 was used in the next step, the asymmetric Strecker 
reaction with (R)-α-phenylglycinol as a chiral inductor.138-145139140141142143144145Here, the isomers 
29/30 were formed in ~1/1 ratio, which means that the chiral induction did not 
happen  (Fig. 3.3).  Separation  of  29/30  was  performed  by flash column chromato- 
 
 
 
Fig. 3.3. Fragment of HPLC chromatogram of the reaction mixture 29/30. 
 
graphy and the absolute configuration of the obtained isomers was established by X-
ray analysis of 30 (Fig. 3.4).146 
ЬMmм 
Fig. 3.4. Molecular structure of 30. 
 
Quite useful for the synthesis was the observation that in methanolic solution 
of 29 the isomer 30 appeared with  time (Scheme 3.6).  This  process  was  proven  by  
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Scheme 3.6. Isomerization of 29 in MeOH.  
 
1H- and 19F-NMR and analytical HPLC (Table 3.2). In 36 h at 20 °С, about 20% of 
29 dissolved in MeOH was converted into 30. At 65 °С the process occurred faster, 
and the state of equilibrium 29/30 = 1/4 was reached in 3 h. 
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Table 3.2. Fragments of HPLC chromatograms of 29 under various incubation conditions. 
 
isomerization conditions HPLC chromatogram 
а) MeOH, 20 oC, 5 min  
 
b) MeOH, 20 oC, 36 h  
 
c) MeOH, 65 oC, 3 h 
 
 
 
The observed isomerization allowed to convert the isomer 29 completely into 
the target compound 30 (Scheme 3.7), hence the yield of 30 was raised from 53% to 
90% (calculated on 26). 
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Scheme 3.7. The process of converting of isomer 29 into 30. 
  
  Later, upon scale-up, the synthesis of 30 was optimized even further. The 
problem was in the inapplicability of flash chromatographic separation of 29/30 
(difference in Rf ‹ 0.05) when working on a large scale. For instance, to separate 5 g 
of 29/30 entirely, a column with a length of 1 m and width 10 cm was used. 
Obviously, to separate 100 g of this mixture, a more convenient procedure had to be 
applied. Therefore, conditions for separation of 29/30 by crystallization were found 
(see Experimental Part).  
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The last synthetic steps were rather trivial. The isomer 30 was oxidized by 
Pb(OAc)4, and subsequent hydrolysis of the Schiff base 31 in 20% HClaq 
accomplished the synthesis of 20.  
Noteworthy, in the 13С-NMR spectrum of 20 (as well as in 29-30), the signal of 
Сα is a quartet (J(C, F) = 2 Hz). No doubt, this is the result of coupling to fluorine 
atoms, the interaction occurring over 5 bonds (Fig. 3.5). 
C
NH2
COOH
F
F
F
H
18
quartet
5J(C, F) = 2 Hz 
     
Fig. 3.5. Signal of Сα in 13С-NMR spectrum of 20. 
 
 
3.4. Confirmation of the optical purity of CF3-Bpg 
 
It is generally known that amino acids possessing electron-withdrawing 
substituents are prone to racemization.147 Since the stability of the hemiacetal 28 
could be caused by an electron-withdrawing effect of the CF3-group, the amino acid 
20 could have an increased propensity to racemization as well. Taking into account 
the relatively harsh hydrolysis conditions used for 30 (120 °C, 2 h, 20% HCl) during 
the last step of the synthesis, one might have doubts concerning the optical purity of 
20.  
One method, among others,148,149 to determine the optical purity of amino acids 
is the use of lanthanide shift reagents (LSRs).150 The technique is based on the ability 
of Eu, Pr and Yb derivatives to shift the NMR signals of a bound substrate without 
substantially broadening them (in contrast to other lanthanides). This effect is due to 
the formation of a “pseudo-contact” complex between the lanthanide metal and the 
functional groups of the substrate (most often NH2 or OH). Provided that the LSR is a 
chiral compound (possessing a chiral ligand), it can be used to determine the 
enantiomeric excess (ee) of the substrate, since the chemical shifts of the 
diastereomeric complexes of the LSR with different enantiomers are not equal. The 
ee of amino acids can be revealed by converting them first into the corresponding 
methyl esters, which are subsequently analyzed by LSR. Determination of ee is 
performed by integrating the signals of the CO2Me-groups of the methyl ester in the 
1H-NMR spectrum. 
Since the analysis requires both enantiomers, (R)-α-amino acid 36 was 
synthesized first (Scheme 3.8). 
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Scheme 3.8. Synthesis of 36. 
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Next, 36 and 20 were converted into the hydrochlorides 37*HCl/38*HCl by 
standard МеОН/SOCl2 treatment. The target methyl esters 37 and 38 were obtained 
from the corresponding hydrochlorides by treating with NEt3 (Scheme 3.9). 
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Scheme 3.9.  Syntheses of 37 and 38. 
 
As LSR the compound 39 was used: 
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The results of the LSR assisted purity check of 38 are summarized in Table 3.3. They 
undoubtedly prove 38, and hence amino acid 20, to be pure (S)-enantiomers.  
 
Table 3.3. Signal of СO2Me group in a 1H-NMR spectrum (CDCl3) of а) mixture 37/38; b) mixture 37/38 
(0.05M/0.05M) in the presence of 39 (0.05M); c) 38 (0.1M) in the presence of 39 (0.05M).  
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3.5. Synthesis of a model peptide derivative of CF3-Bpg 
 
To confirm the possibility of incorporating 20 into the peptide backbone, the 
simplest peptide model - diamide 40 - was synthesized (Scheme 3.10). The obtaining 
of monoamide 41 by reaction of 38*НСl with AcCl/NEt3 was performed without 
troubles. In the next step, however, the target diamide 40 was obtained with an 
unexpectedly low yield of ~20%. 
 
MeNH2 O
NH
CF3
NH2 CO2Me
CF3
N
H
O
CO2Me
CF3
N
H
O
O
N
H
NEt3
AcCl
+
38*HCl 41 (80%) 40 (20%)
*HCl
42
 
 
Scheme 3.10.  Synthesis of 40. 
 
The amide 42 was also identified among the reaction products, and its presence 
suggested an explanation of the poor yield of 40. Since the reaction was carried out 
under rather drastic conditions (100 °С) using excess of MeNH2, the compound 40, 
after being formed, reacted further with methylamine (Scheme 3.11).  
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Scheme 3.11. Suggested mechanism of amide 42 formation in the reaction of 40 with excess of methylamine at 100 °C. 
 
The synthesis of diamide 40 proved that it is possible to incorporate 20 into 
polypeptides. 
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PART 4 
FIRST 19F-NMR LABELS FOR PROLINE SUBSTITUTION IN PEPTIDES 
 
 In the following chapter the syntheses of 3,4- and 4,5-
(trifluoromethylmethano)-prolines and precursors to 2-(trifluoromethyl)-proline are 
described. These conformationally restricted amino acids were designed as 19F-NMR 
labels for Pro substitution in membrane-bound peptides. 
The results described in this chapter have been published in the following 
manuscripts: 
Grygorenko O. O., Kopylova N. A., Mykhailiuk P. K., Meißner A., Komarov I. V. An 
approach to 2-cyanopyrrolidines bearing a chiral auxiliary // Tetrahedron: 
Asymmetry. - 2007. - Vol. 20. - P. 290-297; 
Mykhailiuk P. K., Afonin S., Palamarchuk G. V., Shishkin O. V., Ulrich A. S., 
Komarov I. V. Synthesis of trifluoromethyl-substituted proline analogues - new 19F-
NMR labels for peptides in polyproline II conformation // Angew. Chem. - 2008. - in 
press; 
Mykhailiuk P. K., Afonin S., Ulrich A. S., Komarov I. V. A convenient route to 
trifluoromethyl-substituted cyclopropane derivatives // Synthesis. - 2008. - in press. 
 
 
4.1. Design of the target compounds 
 
The location of proline residues in proteins is peculiar: they are most frequently 
found in loops and in flanking positions of stable secondary structure elements (α-
helices, β-strands), as well as in various turns.151,152 This location is a consequence of 
two major structural properties of Pro: first, the lack of hydrogen on the α-amino 
group prevents hydrogen-bonding within a polypeptide, and second, the cyclic nature 
of the side chain reduces the conformational freedom and typically restricts the 
torsion angle φ to -63° (±15°).153 Pro-rich peptides (PRPs) in aqueous solvents often 
exist in a left-handed “poly-L-proline II” (PPII) conformation, with φ ~ -75°, ψ ~ 
150° and ω = 180°.154 Stable PPII sequences reflect the functional dichotomy of PRP: 
they either act as structural building blocks or they are constituents of specific 
peptide-peptide and peptide-ligand recognition sites.155 Taking into account the 
importance of PRPs, and the absence of the promising 19F-labels for Pro substitution 
in the literature (Chapter 1.3.2), the design of such compounds is of special 
importance. 
In the case of Pro, however, it is not trivial to design such label with a fixed 
CF3-group, that would not perturb the peptide conformation. The hypothetical 19F-
labels 43 and 44 (Fig. 4.1), for instance, are conformationally rigid amino acids and 
therefore possess  fixed CF3-groups. However, one can state that 43-44 will influence  
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Fig. 4.1. Hypothetical conformationally rigid 19F-labels 43 and 44 with fixed CF3-group.  
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the native peptide conformation, since in their known non-substituted analogues 
45156,157-46158,159 the angle ϕ adopts values of either ± 
29°(45), or ±36 ~ ±51° (46), which is far away from the 
normal range around -63° (±15°) for Pro.153 Thus, 43-44 
are not suitable 19F-labels. In other hypothetical 19F-
NMR labels, conformationally non-rigid amino acids 47(а,b) the angle ϕ, on the 
contrary to 45-46, is not fixed (Fig. 4.2). However, the position of the CF3-group is 
not fixed either. Hence, 47(а,b) are also not proper 19F-labels.  
  
N
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H
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47а 47b  
 
Fig. 4.2. Hypothetical 19F-labels 47(a,b) with flexible CF3-group. 
 
In this thesis a library of CF3-substituted conformationally restricted Pro 
analogues 48-50 was proposed (Fig. 4.3) to produce potential 19F-labels for Pro 
substitution. 
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Fig. 4.3. Designed  19F-NMR labels for substitution of Pro in peptides. 
 
In amino acid 48 the position of the СF3-group is well defined with respect to 
the molecular backbone, since it is directly attached to Cα. However, a spatial 
proximity of the bulky electron-withdrawing СF3-group to the aminocarboxylate 
moiety reduces the reactivity of the amino group in 48 and could alter the steric and 
electronic environment of the peptide backbone.160,161,162  The isomers 49-50, on the 
contrary to 48, possess a CF3-group which is sufficiently distant from the peptide 
backbone to prevent its perturbation and influence the reactivity of the 
aminocarboxylate moiety. The angle ϕ in these compounds, in contrast to 43-44, is 
not fixed. Moreover, since the conformational mobility of 49-50 is restricted by the 
presence of the rigid three-membered ring, the position of the CF3-group is better 
fixed than in 47(a,b). However, it may still turn out that the partially flexible non-
rigid location of the CF3-group in 49-50 may cause some ambiguities in the 
interpretation of the 19F-NMR spectra.  
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4.2. 2-(Trifluoromethyl)-proline 
4.2.1. Planning the synthesis of 2-(trifluoromethyl)-proline 
At the time this work was started, there were three compounds 51,163 52,164 
53165,166  described  in  the  literature,  which  are  structurally  similar to 48 (Fig. 4.4).  
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Fig. 4.4. 2-Trifluoromethylproline (48) and known structure-related compounds (51, 52, 53).163-166 
 
Synthesis of 51, 52 and 53 included 4-5 steps from commercially available materials, 
and all three compounds were known in racemic form only. Therefore, the 
fundamentally different strategies to obtain 48 were proposed.  
The first approach allowed obtaining rac-48 in only 3 steps from the 
commercially available proline methyl ester hydrochloride (Scheme 4.1). This 
method was based on the known addition of СF3SiMe3 to imines (Scheme 4.2).167,168  
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Scheme 4.1. Approach 1: retrosynthetic analysis of 48 in racemic form. 
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Scheme 4.2. An example of the reaction between СF3SiMe3 and non-activated imines in the presence of fluoride-
anion.167,168 
 
For synthesis of optically pure 48, an approach (Scheme 4.3) based on the 
known cyclization of γ-halogenketones into the corresponding diastereomeric 
aminonitriles (Scheme 4.4)169 was proposed.  
 
N
H
CF3
COOH N
Ph
CF3
CN
CF3
Br
O
48  
 
Scheme 4.3. Approach 2: retrosynthetic analysis of (S)-48. 
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Scheme 4.4. An example of converting of the γ-halogenketone into the corresponding cyclic aminonitriles.169 
 
 
4.2.2. Synthesis of 2-(trifluoromethyl), 2-(nitrile)-pyrrolidine skeleton 
 
Approach 1: The compound 54 was easily synthesized from proline methyl 
ester in one step according to  the literature procedure (Scheme 4.5).170   
 
N
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55%
 
 
Scheme 4.5. Synthesis of 54.170 
 
In the following reaction, - addition of СF3SiMe3 to the double C=N bond of 54 
- however, a mixture of products was obtained. Notably, in the 1H-NMR spectrum 
there were no signals of CO2Me-group detected. At the same time GC-MS analysis 
revealed the presence of two peaks having molecular masses of 165 and 254 (m/z) 
respectively. The interpretation of these products is illustrated in Fig. 4.5.  
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Fig. 4.5. Structural interpretation of signals with m/z of 165 and 254, seen in GC-MS analysis of the mixture obtained 
after addition of СF3SiMe3 to 54. 
 
This result suggested that in 54 the CO2Me-group was more reactive than the 
C=N bond towards СF3SiMe3 (Scheme 4.6). 
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Scheme 4.6. Reaction beetwen СF3SiMe3 and 54 at -50 °С catalyzed by Me4NF. 
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Formation of the mixture 55/56 is a rather strange result, because normally a 
reaction between СF3SiMe3 and a carboxymethyl group requires at least room 
temperature.171 
Approach 2: For the starting γ-halogenketone 57 two synthetic roots are 
described in the literature   (Scheme 4.7).172,173    
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Scheme 4.7. Known syntheses of 57.172,173 
 
The first method is based on trifluoroacetylation of 4-bromobutyryl chloride, 
followed by subsequent hydrolysis of the corresponding intermediate (Scheme 4.7, 
а). However, this reaction was not reproducible, since complex mixtures were 
obtained every time. An alternative way to synthesize 57 (Scheme 4.7, b) was not 
reproducible either. Under conditions described in the literature,173,174 an addition of 
CF3SiMe3 to γ-butyrolactone in the presence of Me4NF*3H2O did not happen. 
Therefore, another catalyst was used - anhydrous CsF, - which allowed to obtain 58 
in 65% yield (Scheme 4.8). 
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Scheme 4.8. Synthesis of 58 according to a) literature procedure174; b) modified procedure. 
 
The next step - opening of the tetrahydrofuran ring of 58 - was problematic as 
well. Even after refluxing of 58 with 48% aq. HBr over 60 h the reaction did not 
proceed at all (however, according to the literature procedure it had to be finished in 
24 h). The reaction stopped at the stage of formation of alcohol 59, whose relative 
stability might be caused by an electron-withdrawing effect of the CF3-group. 
Addition of catalytic amounts of ZnBr2 accelerated the reaction and allowed to obtain 
57 in 30% yield (Scheme 4.9). 
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Scheme 4.9. Synthesis of 57. 
  
33
The key step of the synthesis - cyclization of 57 with aminonitrile 60 to 
produce the corresponding 2-trifluoromethyl-pyrrolidines - was not 
productive. Although the target compounds 61(а,b) were detected in 
the reaction mixture by NMR and GC-MS, the isolated yield was too 
low (1%). This might be caused by the high reactivity of the carbonyl 
group in 57, therefore reaction takes place with any of the nucleophiles present in the 
reaction mixture. The present hypothesis was proven by isolation of 62 along with 
61(a,b) (Scheme 4.10).  
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Scheme 4.10.  Synthesis of 61(a,b) and 62. 
 
Unfortunately, the proposed synthetic strategies to 48 (Scheme 4.1, Scheme 
4.3) could not be realized, since the selected key reactions either led to unexpected 
products or produced low yields of the target compounds.*  
 
 
4.3. 3,4-(Trifluoromethylmethano)-prolines 
 
4.3.1. Planning the synthesis of 3,4-(trifluoromethylmethano)-prolines 
 
To design the synthesis of 49 rationally, the synthetic methods to already 
known compounds 69,175,176 70,177 71,178,179 resembling the structure of 49 closely, 
(Fig. 4.6) were analyzed. 
 
                                                 
* While this work was in progress, the publication “Chaume G., Van Severen M. C., Marinkovich S., Brigaud T. 
Straightforward synthesis of (S)- and (R)-α-trifluoromethyl proline from chiral oxazolidines derived from ethyl 
trifluoropyruvate // Org. Lett. - 2006. - V. 8. - P. 6123-6126” appeared. 
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The authors reported the synthesis of (S)-48 in 6 steps from ethyl 3,3,3-trifluoropyruvate 63. Notably, compounds 64-67 
were mixtures of diastereomers, which were separated only at the stage of the product 68. 
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Fig. 4.6. 3,4-(Trifluoromethylmethano)-proline (49) and known compounds with related structures (69, 70, 71).175-179 
 
There are different strategies to 69, 70, 71 reported in the literature, but one 
approach, among others, is the same for all compounds. It relies on the addition of the 
corresponding carbenes to protected derivatives of 3,4-dehydroproline (Scheme 
4.11). 
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Scheme 4.11. Known syntheses of 69-71.176-177 
 
Knowing that the photolytic addition of СF3CHN2 to alkenes is feasible 
(Scheme 4.12),180,181,182 a key step in the retrosynthetic scheme of 49 was suggested to 
be based on photochemical trifluoromethylcyclopropanation of protected 3,4-
dehydroproline (Scheme 4.13). 
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Scheme 4.12. Known example of the photolytic reaction between СF3CHN2 and alkenes.180 
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Scheme 4.13. Retrosynthetic analysis of 49. 
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4.3.2. Photochemical addition of СF3CHN2 to 3,4-dehydroproline derivative 
 
The starting alkene 72 was synthesized from commercially available 4-
hydroxyproline according to the literature procedure (Scheme 4.14).183 
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Scheme 4.14. Synthesis of 72.183 
 
The crucial step in the synthesis of 49 - photochemical decomposition of 
СF3CHN2 and subsequent addition of CF3CH: to the С=С double bond of 72 - was 
not productive. Even after irradiation of the reaction mixture during 1 month, the 
formation of 74 was not observed (Scheme 4.15). 
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Scheme 4.15. Photolytic reaction between СF3CHN2 and 72 does not lead to 74. 
 
Due to zero yield of 74, the procedure of trifluoromethylcyclopropanation of 
alkenes was modified. 
 
 
4.3.3. Modification of the procedure of trifluoromethylcyclopropanation of 
alkenes 
 
Often, cyclopropanation of C=C double bonds utilizes metallocatalysis.184,185 
The most common catalyst in these reactions is Rh2(ОАc)4,186 although for 
asymmetric cyclopropanation rhodium catalysts bearing chiral ligands can be 
used.187,188 Syntheses of СF3-substituted cyclopropane derivatives by addition of the 
corresponding СF3-substituted carbenes to double С=С bonds are also known 
(Scheme 4.16).189-194190191192193194 
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Scheme 4.16. Some known examples of trifluoromethylcyclopropanation of alkenes catalyzed by Rh2(ОАc)4.189,193 
 
Surprisingly, there was no information in the literature concerning the use of 
metallocatalysts while working with СF3CHN2. Therefore, to test the feasibility of 
this method, a set of alkenes with different types of C=С double bonds was 
systematically examined (Fig. 4.7). 
 
O AcOPh AcHN CO2Me  
 
Fig. 4.7. Model alkenes selected for trifluoromethylcyclopropanation by СF3CHN2 in the presence of metal catalysts. 
 
Styrene and 3,4-dihydropyran, possessing activated C=С bonds, indeed reacted 
with СF3CHN2 in the presence of Rh2(ОАc)4. The products (±)75(а,b) and (±)76(а,b) 
were isolated by distillation, isomers cis-(75b, 76b) and trans-(75а, 76а) being 
separated by flash column chromatography (Scheme 4.17). 
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Scheme 4.17. Syntheses of (±)75(a,b) and (±)76(a,b). 
 
The determination of the relative configuration of separated isomers was based 
on the rule that in cyclopropane derivatives the 3Jcis(H, H)-constant is always larger 
than the 3Jtrans(H, H)-constant.195 In the 1H-NMR spectrum of (±)75а, the benzylic 
proton has one 3Jcis(H, H) = 9.3 Hz and two 3Jtrans(H, H) = 5.6 Hz constants, therefore 
the configuration of (±)75а is trans (Fig. 4.8). The benzylic proton of the cis-isomer 
(±)75b has, on the contrary, one 3Jtrans(H, H) = 8.0 Hz and two 3Jcis(H, H) = 8.4 Hz 
constants (Fig. 4.8). 
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Fig. 4.8. Analysis of the 3J(Н, Н)-constants in cyclopropane fragments of 75а and 75b. 
 
The same is true for (±)76(а,b). The 1H-NMR spectrum of (±)76а shows for 
the proton at С(1) 3Jcis(H, H) = 7.6 Hz and 3Jtrans(H, H) = 2.0 Hz, which undoubtedly 
assigns this isomer to be trans. Obviously, 76b is in this case the cis-isomer. 
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Fig. 4.9. Analysis of the 3J(Н, Н)-constants in the cyclopropane fragment of 76а. 
 
The evaluation of the relative configurations of (±)75(а,b) and (±)76(а,b) was 
in full accordance with the formation of the less sterically constrained trans-isomers 
as the major reaction products: 75а/75b = 2/1 and 76а/76b = 2/1. 
In the case of vinylacetate the reaction proceeded as well, however, the 
products (±)77(а,b) could not be separated due to their high volatility (Scheme 4.18). 
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Scheme 4.18. Synthesis of (±)77(a,b). 
 
The cyclopropanation of cyclohexene was not productive with Rh2(ОАc)4, but 
the cyclopropanes (±)78(а,b) were obtained with a moderate yield (40%) using 
CuOTf196,197 as a catalyst (Scheme 4.19). The high volatility of isomers (±)78(а,b) 
hindered their separation, like in (±)77(а,b). 
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Scheme 4.19. Synthesis of (±)78(a,b). 
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To demonstrate the practical suitability of the present approach, 
both diastereoisomers of trifluoronorcoronamic acid - analogues of 
naturally occurring norcoronamic acid 80, which is a building block 
of the toxin norcoronatine from Pseudomonas syringae, were 
synthesized.198  
Cyclopropanation of the corresponding derivative of methyl acrylate199 in the 
presence of Rh2(ОАc)4  led to the desired products (±)79(а,b) (Scheme 4.20). 
 
CF3CHN2
Ph2(OAc)4
AcHN CO2Me AcHN
CF3
CO2Me AcHN
CF3
CO2Me
79а 79b
(15%)
79а / 79b = 1/1chromatographic
separation
1)
2)
+
 
 
Scheme 4.20. Synthesis of  (±)79(a,b). 
 
Notably, the choice of catalyst was crucial in this transformation, as the use of 
CuCl yielded compound 81 as the major reaction product (Scheme 4.21). 
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Scheme 4.21. Synthesis of 81. 
 
Treating (±)79а in 20% HCl at 80 °C for 30 h afforded the amino acid (±)82а, 
with spectral characteristics identical to those described previously for the trans-
trifluoronorcoronamic acid.200 The cis-trifluoronorcoronamic acid (±)82b was 
obtained from (±)79b following the same procedure (Scheme 4.22).* 
 
AcHN
CF3
CO2Me
AcHN
CF3
CO2Me
NH2
CF3
COOH
NH2
CF3
COOH
79а
79b
HCl
82а
82b
HCl
*HCl
*HClquant.
quant.
 
 
Scheme 4.22. Synthesis of  (±)82(a,b). 
                                                 
* As the present work was in progress the publication describing first example of catalytic trifluoromethylcarbene 
generation and its stereoselective addition to styrene derivatives appeared: Le Maux P., Juillard S., Simonneaux G. 
Asymmetric synthesis of trifluoromethylphenil cyclopropanes catalized by chiral metalloporphyrins // Synthesis. - 
2006. - Vol. 10. - P. 1701-1704. 
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Notably, the authors observed a formation of exclusively trans-cyclopropane products. 
NH2 COOH
80
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4.3.4. Synthesis of 3,4-(trifluoromethylmethano)-prolines 
 
Since the procedure of CF3-cyclopropanation of alkenes was demonstrated to 
be successful, this reaction was applied for the synthesis of 49(а,b). However, the 
transformation of 72 was found to be rather dependent on the catalyst nature. For 
example, in the presence of CuCl or Rh2(OAc)4, compound 83 was the main reaction 
product (Scheme 4.23). 
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Scheme 4.23. Synthesis of 83. 
 
In the presence of CuОTf, however, a complex mixture was observed, from 
which compounds 74, 83 and 84а were isolated by HPLC (Scheme 4.24).  Obviously, 
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Scheme 4.24. Reaction beetwen 72 and CF3CHN2 catalized by CuОTf. 
 
in contrast to CuCl and Rh2(OAc)4, the use of CuOTf increased the reactivity of the 
C=С bond towards CF3CH:, however, the reaction with Boc-group still took place. 
To circumvent this problem an excess of CF3CHN2 was used, which allowed to 
obtain the target products 84(а,b) in 15% yield (Scheme 4.25). 
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Scheme 4.25. Synthesis of 84(a,b). 
 
Since the cleavage of the CF3CH2OCO-group from a nitrogen atom has not yet 
been described in the literature, a lot of experimentation was needed to find optimal 
conditions for this transformation. Hydrolysis under basic conditions was tried first. 
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Unfortunately, together with the cleavage of CF3CH2OCO-group, an extensive 
epimerization at Сα occurred as well (Table 4.1).  
 
Table 4.1. Cleavage of the carbamate group of 84а under basic conditions. 
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№ reagent quantity 
(eq.) 
t  
(°C) 
time  
(h) 
conversion 
(%)* 
49а/85a 
1. NaOH (H2O-THF) 4  25 20 0 - 
2. NaOH (H2O-THF) 4  80 10 80 5/1 
3. NaOH (H2O-THF) 4  80 20 100 4/1 
4. NaOH (H2O-ТHF) 3  80 10 60 6/1 
5. NaOH (H2O-MeOH) 4  80 10 70 3/1/1(86) 
* according to 19F-NMR. 
 
Notably, while carrying out the hydrolysis of 84a in an H2O-
MeOH mixture together with 49а/85a, a considerable amount of 86 
formed as well (Table 3.1, № 5). In order to reduce formation of the 
epimerized product 85a, while retaining a high reaction conversion, 
an acidic hydrolysis was tried next (Table 4.2).  
 
Table 4.2. Cleavage of carbamate group of 84а under acidic conditions.  
 
№ reagent quantity 
(eq.) 
t  
(°C) 
time  
(h) 
conversion 
(%)* 
49а/85a 
1. HCl (36 %, H2O) excess 25 20 0  - 
2. HCl (36 %, H2O) excess 110 20 0  - 
3. HBr (48 %, H2O) excess 25 20 0  - 
4. HBr (48 %, H2O) excess 126 10 95 5/1 
5. HBr (48 %, H2O) excess 126 8 93 7/1 
6. HBr (48 %, H2O) excess 126 6 90 9/1 
7. HBr (48 %, H2O) excess 126 4 70 11/1 
* according to 19F-NMR. 
 
The best result was observed while performing hydrolysis in 48% aq. HBr for 6 
h (Table 3.2, № 6). After purification of the reaction mixture on Dowex-50, two 
fractions were obtained. Amino acid 49а was isolated from the first one with a yield 
of   40%   and  purity  of  90%   (Scheme 4.26).   The   second   fraction,  containing a 
N
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Scheme 4.26. Synthesis of 49a. 
 
considerable amount of 85a, was converted into the corresponding Fmoc-derivatives 
87(а,b), which were separated by HPLC (Scheme 4.27). 
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Scheme 4.27. Synthesis of 87(a,b). 
 
Interestingly, under the conditions identical to those used for hydrolysis of 84a, 
isomer 84b afforded pure 49b (Scheme 4.28). 
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Scheme 4.28. Synthesis of 49b. 
 
 
4.3.5. Evaluation of stereoconfiguration of the synthesized amino acids 
 
The formation of four stereoisomers of 49, possessing an (S)-configuration at 
the aminocarboxylate moiety, is theoretically possible (Fig. 4.10). 
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Fig. 4.10. Theoretically possible isomers of 49 with (S)-configuration at С(2). 
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First, the configuration at the С(1) and С(5) atoms in the cyclopropane rings of 
49(a,b) was established. For this the 1H-NMR spectra of 49(a,b) and the known 
structurally related amino acids 88, 89, 71a, 71b (Fig. 4.11) were compared.176,178,179 
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Fig. 4.11. Compounds 88, 89, 71(а,b) and corresponding 3J(Н, Н)-constants between protons at С(2) and С(1).176,178,179 
 
In the 1H-NMR spectra of three trans-methanoprolines 88, 89, 71а the signal of 
the proton at C(2) is either singlet (71a) or pair of singlets (two rotamers are observed 
for 88, 89). In contrast, in the 1H-NMR spectrum of the cis-isomer 71b the same 
proton is a doublet (3J(H, H) = 4.5 Hz). In the 1H-NMR spectrum of 49a the proton at 
C(2) is a singlet, but in 49b a doublet with 3J(H, H) = 4.4 Hz. This confirms that 49a 
possesses the cyclopropane fragment in trans-configuration with respect to the 
COOH-group, while 49b in cis-configuration (Fig. 4.12). 
 
 
 
 
 
Fig. 4.12. 1H-NMR spectra of 49а and 49b and assignment of the observed signals. 
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Next question to be answered was the configuration at C(6) in 49(a,b). As it 
was mentioned earlier (Chapter 4.3.3) in cyclopropane derivatives 3Jcis(H, H)-
constant is larger than the corresponding 3Jtrans(H, H)-constant. For both isomers 
49(a,b) two types of coupling constants are seen (Fig. 4.13). 
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Fig. 4.13. Analysis of the  3J(Н, Н)-constants in the cyclopropane ring of both 49а and 49b. 
 
This observation suggests that in 49(a,b) the proton at C(6) has an anti-orientation 
relative to the protons at C(1) and C(5). For the isomer 49b this assumption was 
readily confirmed by an NOE between the protons at C(4) and C(6) (Fig. 4.14). 
Although in 49a the analogous correlations were not detected, they were found in the 
NOESY-spectrum of 87a (Fig. 4.14). 
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Fig. 4.14. The Nuclear Overhauser Effect (NOE) between protons at C(4) and C(6) in 49b, and the NOESY correlation 
between protons at С(6) and С(4) in 87a confirm the stereoconfiguration of these compounds. 
 
 
4.4. 4,5-(Trifluoromethylmethano)-prolines 
 
4.4.1. Planning the synthesis of 4,5-(trifluoromethylmethano)-prolines 
 
To plan the synthesis of 50 rationally, synthetic methods to the known 
structurally related amino acids 90201,202 and 91а, 91b203,204 (Fig. 4.15) were analyzed 
first. 
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Fig. 4.15. 4,5-(Trifluoromethylmethano)-proline (50) and known compounds with similar structure (90, 91a, 91b).201-204 
 
The key step in the synthesis of 90 is cyclopropanation of 92 with 
ethyldiazoacetate in the presence of Rh2(OAc)4 (Scheme 4.29). 
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Scheme 4.29. Synthesis of the known compound 90.201,202 
 
Concerning the synthesis of 4,5-methanoprolines 91(а,b), one approach among 
others relies on the cyclopropanation of the unsaturated substrate 93 using Simmons-
Smith reaction (Scheme 4.30).203 
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Scheme 4.30. Known synthesis of the compounds 91(а,b).203 
 
Both transformations described above are based on cyclopropanation; 
following them in the synthesis of 50 it was decided to use 
trifluoromethylcyclopropanation as well (Scheme 4.31).  
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Scheme 4.31. Retrosynthetic analysis of 50. 
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4.4.2. Synthesis of 4,5-(trifluoromethylmethano)-prolines 
 
The starting compound 73 was obtained as a side product in the synthesis of 
49(a,b) (Scheme 4.14). Addition of CF3CH: to the C=С double bond in 73 occurred 
rather fast, independently on the catalyst (CuCl, Rh2(ОАc)4 or CuOTf), in contrast to 
the analogous reaction of 72 (Chapter 4.3.4). Apparently, this difference is a 
consequence of the presence of the N-Boc group directly at the double bond in 73.  
The best results were obtained using the less active catalyst CuCl, since in the 
presence of Rh2(OAc)4 or CuOTf an extensive formation of unidentified side 
products was observed. Using 1Н- and 19F-NMR for reaction monitoring, the process 
was stopped after the disappearance of the signals from the starting material 73, 
which allowed to obtain only the target products 97(a,b,c) (Scheme 4.32). 
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Scheme 4.32. Synthesis of 97(a,b,c). 
 
By using an excess of CF3CHN2, however, the formation of a rather complex 
mixture was observed, from which, along with 97(a,b,c), compound 98 was isolated 
as well: 
 
OO
N CO2Me
CF3
CF3
98  
 
The last steps of the synthesis were rather trivial: basic hydrolysis of СO2Me-
groups followed by cleavage of Boc-groups (TFA/CH2Cl2) led to the formation of the 
target amino acids 50 (a,b,c)*TFA (Scheme 4.33). 
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Scheme 4.33. Synthesis of 50(b,c)*TFA and 50a. 
 
Notably, while 50а*TFA was converted into its zwitterionic form 50a by 
cation-exchange chromatography on Dowex-50 resin, two other isomers under the 
same conditions partially (50b*TFA) or completely (50с*TFA) decomposed. 
Unfortunately, the products of decomposition were not isolated, however, typical 
triplets in 19F-NMR spectra and signals at 5.0-5.5 ppm in 1H-NMR spectra indicated 
that cleavage of the cyclopropane ring may have happened (Scheme 4.34). 
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Scheme 4.34. Suggested mechanism and NMR evidence for cleavage of the cyclopropane ring in 50(b,c) under acidic 
conditions. 
 
Interestingly, while in the 13С-NMR spectra of both 50(а,b)*TFA the signal of 
Сα is a singlet, in 50c*TFA the same carbon produces a quadruplet. This is a result of 
coupling to fluorine atoms, the interaction occurring through five bonds with 5J(C, F) 
= 4 Hz (Fig. 4.16). 
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Fig. 4.16. Signal of Cα in the 13C-NMR spectra of 50(a,b,c)*TFA. 
 
4.4.3. Evaluation of the stereoconfiguration of the synthesized compounds 
 
The formation of four stereoisomers of 50, possessing the (S)-configuration at 
the aminocarboxylate moiety, is theoretically possible (Fig. 4.17). 
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Fig. 4.17. Theoretically possible isomers 50 with (S)-configuration at С(3). 
 
The major experimental evidence proving a configuration of the stereocenters 
in 50a is the presence of a cross-peak between 6-H and 4-Ha in the NOESY spectrum. 
These protons can be in spatial proximity in only one case out of four (Fig. 4.18). 
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Fig. 4.18. NOESY correlation between protons 4-Нa and 6-Н in 50а determines the stereoconfiguration of this 
compound. 
 
Structure assignment of 50b was carried out on its precursor 99b. The NOESY 
correlations in 99b undoubtedly prove its structure (Fig. 4.19). 
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Fig. 4.19. Key NOESY correlations in 99b. 
 
The established structure was additionally confirmed by X-ray analysis of the 
precursor 97b (Fig. 4.20).205 
 
 
Fig. 4.20. Molecular structure of 97b. 
 
Determination of the relative configuration of the stereocenters in 50c was also 
performed on its precursor 99c. In the NOESY spectrum of 99c the area of 
correlation peak between 4-Нa and 5-Н is larger than that of the correlation between 
4-Нb and 5-Н (Fig. 4.21). This proves that the protons 5-H and 4-Нa are in a syn-
orientation. Thus, 99c possesses the same configuration of the cyclopropane ring with 
regard to the COOH group as its isomer 99b. Apparently, 99c differs from 99b only 
by the configuration at C(6). 
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Fig. 4.21. Key NOESY correlations in 99c. 
 
The established structures of 50a and 99(b,c) are in full accordance with the 
observed NOESY-correlations of protons in their cyclopropane moieties (Fig. 4.22). 
In both 50а and 99b, the correlation peak between 1-Н and 5-Н (syn-protons) is 
larger than that between 1-Н and 6-Н (anti-protons). In contrast, in 99c both 
correlations are of the same strength, due to the syn-arrangement of all three protons: 
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Fig. 4.22. NOESY correlations of protons in the cyclopropane rings of 50а, 99b and 99c. 
 
The proposed structures were additionally confirmed by the multiplicity of the 
proton at the respective C(1) in the 1H-NMR spectra of 50(a,b,c)*TFA (Fig. 4.23). In 
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Fig. 4.23. Multiplicities of proton at С(1) and respective coupling constants in 50(а,b,c)*TFA are in full accordance 
with the established structures of these isomers. 
 
50a*TFA, the signal of the 1-H proton is a doublet of doublets (3Jcis = 6.4 Hz, 3Jtrans = 
2.0 Hz), which is in accordance with an anti-orientation of 6-H with regard to 1-Н 
and 5-Н. In 50b*TFA the same situation is observed, the 1-Н proton signal is a 
doublet of doublets (3Jcis = 6.0 Hz, 3Jtrans = 2.0 Hz). In contrast to 50(a,b)*TFA, in 
50с*TFA the 1-H proton peak is a triplet with a characteristic constant  3Jcis = 6.0 Hz, 
which again confirms that all the three cyclopropane protons are in a syn-
configuration.  
The structure of 98 was determined based on the correlations between protons 
6-Н and 3-Н; 6-Н and 4-Нb in the NOESY spectrum (Fig. 4.24). 
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Fig. 4.24. Key NOESY correlations in 98. 
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Later, the established structure was confirmed by X-ray analysis of 98 (Fig. 
4.25).206 
 
 
 
Fig. 4.25. Molecular structure of 98. 
 
 
 
4.5. Selection of the optimal 19F-NMR label (СF3-MePro) 
 
In principle, each isomer of the synthesized compounds 49 and 50 could be 
used   as  a  19F-label  (Fig.  4.26).  However,  the  amino acids   49(a,b)  are  not  that 
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Fig. 4.26. Synthesized amino acids 49(а,b) and 50(а,b,c)*TFA and the selected 19F-label 50а*TFA. 
 
preferable, because of the poor total yield of their synthesis. The isomers 
50(b,c)*TFA are not stable at low pH (as it became apparent during chromatography 
on Dowex-50), which may cause problems at the stage of peptide synthesis. In 
contrast, 50a*TFA (CF3-MePro) is stable at both low and high pH, and was therefore 
selected as a 19F-label for substitution of Pro in peptides. 
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PART 5  
APPLICATIONS OF THE SYNTHESIZED 19F-NMR LABELS IN PEPTIDE 
STUDIES 
 
In this part the practical application of the new 19F-labels 20 and 50а is 
highlighted. First, to address the question about the utility of 20 in peptide studies, 
this label was incorporated into the structurally and functionally well characterized 
antimicrobial peptides: gramicidin S (GS) and peptidyl-glycylleucine-carboxyamide 
(PGLa). The synthesized 19F-labelled analogues of GS and PGLa were analyzed by 
antimicrobial assays, circular dichroism, and solid state 19F-NMR to assess the 
functional and structural influence of Val/20, Leu/20, Ile/20, Ala/20 substitutions. It 
was demonstrated that 20 fullfils all the requirements for a proper label for solid state 
19F-NMR of polypeptides. Initial structural studies of the cell-penetrating peptide 
“Sweet Arrow Peptide” (SAP) with an as yet unknown structure in the membrane 
bound state were then carried out using 20 and 51a to validate the use of 51a as a 19F-
NMR label as well. Indeed, the potential of 51a for being a proper structural label for 
substitution of Pro in polyproline type II helices (PP II) was shown. 
The results described in this chapter have been described in the following 
manuscripts: 
Afonin S., Mykhailiuk P. K., Komarov I. V., Ulrich A. S. Evaluating the use of CF3-
bicyclopentylglycine as a label for 19F-NMR structure analysis of membrane-bound 
peptides // J. Pept. Sci. - 2007. - Vol. 13. - P. 614-623; 
Mykhailiuk P. K., Afonin S., Palamarchuk G. V., Shishkin O. V., Ulrich A. S., 
Komarov I. V. Synthesis of trifluoromethyl-substituted proline analogues - new 19F-
NMR labels for peptides in polyproline II conformation // Angew. Chem. - 2008. - in 
press. 
 
5.1. Antimicrobial peptide GS 
 
5.1.1. General information about GS 
 
GS is a natural cyclic decapeptide, containing the unusual amino acid ornithine 
(Orn) and the D-enantiomer of phenylalanine (DPhe) (Fig. 5.1). 
 
 
Fig. 5.1. Structural model and amino acid sequence of GS. 
cyclo-(Pro-Val-Orn-Leu-DPhe)2 
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GS is produced by A. migulanus (formerly B. brevis) among other 
antimicrobial peptides via a non-ribosomal biosynthetic pathway.207,208 The peptide 
exhibits a broad spectrum of antibiotic activity against both Gram-positive and 
Gram-negative bacteria, as well as against some fungi.209 It also shows significant 
levels of hemolytic activity, which limits its medical use to topical applications.210 
Structurally GS may be regarded as an anti-parallel β-sheet, flanked by two 
nearly ideal type-II β-turns, and stabilized by 4 intramolecular hydrogen bonds.211 
The positively charged Orn side-chains are positioned on one side of the cyclic 
plane, while the hydrophobic Val and Leu are on the opposite side, which gives rise 
to an amphipatic nature of GS.212 The amphipaticity is considered to be a major 
feature responsible for the strong interaction of GS with lipid membranes. It should 
be mentioned that GS is a typical antimicrobial peptide in a sense that it does not 
require a specific receptor for its interaction with the target (i.e. with the bacterial 
membrane).213 
 
5.1.2. Synthesis of CF3-labelled analogue of GS 
 
GS contains two amino acids which potentially could be substituted by 19F-
label 20 - Leu and Val. As 20 more closely resembles Leu than Val according to 
lipophilicity (Chapter 3.1), and since Leu was previously shown to be successfully 
substituted by both 4F-Phg (3) and 4CF3-Phg (4) without major alterations in the GS 
structure and function,77,80 this amino acid was chosen as a position to test the 
substitution (Fig. 5.2). 
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Fig. 5.2. Amino acid sequences of GS and its CF3-labelled analogue 100 with two equivalent Leu/20 substitutions. 
 
First, compound 20 was Fmoc-protected using standard procedures (Scheme 
5.1).214 
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Scheme 5.1. Synthesis of 101. 
 
The synthesis of peptide 100 was carried out on 2-chlorotrityl resin, starting 
from Fmoc-DPhe (Scheme 5.2).215 
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Scheme 5.2. Attachment of the first amino acid (DPhe) to 2-chlorotrityl resin in the synthesis of 100. 
 
19F-label 20 was successfully incorporated into the peptide in the form of the 
Fmoc-derivative 101, using standard activators TBTU/6Cl-HOBt. The following 
amino acids were incorporated analogously (Scheme 5.3). 
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Scheme 5.3. Synthesis of the linear precursor of 100, the decapeptide 102. 
 
Removal of the Fmoc-group from 102 was followed by cleavage from the 
resin, to give the linear decapeptide 103. The target peptide 100 was obtained by 
cyclization of 103 in solution (104) and subsequent cleavage of the ivDde-protecting 
groups from Orn (Scheme 5.4). 
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Scheme 5.4. Synthesis of 100. 
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During the synthesis, neither degradation nor racemization of 20 was observed, 
and the target 100 was formed as a single diastereomer. Thus, the new 19F-label 20 
was fully compatible with standard protocols of SPPS. Moreover, 20 increased the 
yield of the CF3-labelled GS analogue 4-fold compared to the racemically prone Phg-
based labels 3 and 4.77,80 
 
5.1.3. Influence of CF3-Bpg on the conformation of GS 
 
To examine the conformational preferences of GS and 100, CD spectra of both 
peptides were measured under identical conditions. As can be seen from the Fig. 5.3, 
the CD spectra of GS and 100 are almost identical; hence the 19F-label 20 did not 
perturb the conformation of GS. 
 
 
 
Fig. 5.3. CD spectra of GS and 100 in water-ethanol solution (1/1) at 20 °С, with a peptide concentration of 90 µM. 
 
 
5.1.4. Influence of CF3-Bpg on the orientation of GS in lipid bilayers 
 
To evaluate the applicability of CF3-Bpg (20) for structural peptide studies, 
solid state 19F-NMR spectroscopy was used. To do so, a macroscopically oriented 
sample of 100, reconstituted in DMPC bilayers, was measured at different 
temperatures. The spectra acquired here were compared with 19F-NMR data obtained 
from an analogue of GS that had been previously labelled with 4F-Phg (3) at the very 
same positions of the peptide, as shown in Fig. 5.4.216  
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Fig. 5.4. Solid state 19F-NMR spectra of GS analogues with a) Leu/4F-Phg (3) substitutions; b) Leu/CF3-Bpg (20) 
substitutions (100). Both peptides were reconstituted into macroscopically oriented DMPC bilayers at a peptide/lipid 
ratio of 1/40 (mol/mol). Spectra were measured with the membrane normal aligned parallel to the magnetic field. 
Resonances corresponding to the flipped peptide alignment are highlighted in yellow. 
 
Spectra of GS-analogue labelled with 4F-Phg (3) at both low (18-20 °C) and 
high (30-40 °C) temperatures contained predominantly a single peak (Fig. 5.4,a), 
which corresponds to a flat alignment of GS on the bilayer surface (Fig. 5.5, a). In the 
range of 23-27 °C, however, new signals had been previously found to appear due to 
re-alignment of GS into an upright transmembrane state (Fig. 5.5, b).216 The solid 
state 19F-NMR spectra acquired here for 100 (Fig. 5.4, b) are in full accordance with 
the abovementioned re-alignment of GS, which is induced by the lipid phase 
transition from the gel to the liquid crystalline state. At the temperature intervals of 
18-23 °C and 30-40 °C a single well-resolved triplet signal is seen in the spectra, 
while in the temperature range of 25-27 °C same new broad signal appears, 
suggesting an orientational flip of up to 50% GS molecules. The results obtained 
here, thus prove the suitability of CF3-Bpg (20) for peptide structural studies. 
 
 
 
Fig. 5.5. Different orientations of GS embedded in a DMPC bilayer: a) flat alignment on the membrane surface; b) 
upright transmembrane alignment.216 
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5.2. Antimicrobial peptide PGLa 
 
5.2.1. General information about PGLa 
 
PGLa belongs to the magainin family of antimicrobial peptides, and it is found 
in the skin secretions of the frog Xenopus laevis.217,218,219 This cationic peptide 
possesses high affinity to bacterial membranes and is able to permeabilize them. It is 
supposed that specific receptors are not involved in the process of antimicrobial 
action of PGLa.220 Upon binding to biomembranes PGLa adopts an amphipatic α-
helix conformation as illustrated in Fig. 5.6.221  
 
 
Fig. 5.6. Structural model of PGLa in ideal α-helix conformation and amino acid sequence of PGLa. 
 
 
5.2.2. Synthesis of CF3-labelled analogues of PGLa 
 
PGLa was labelled with 20 at the positions 9 (Ile), 10 (Ala), 13 (Ile) and 14 
(Ala), as the behaviour of the previously used 19F-label 4CF3-Phg (4) at these 
positions had been comprehensively described.80 The corresponding labelled peptides 
106-109 (Fig. 5.7) were synthesized using standard protocols of SPPS on Rink-amide 
resin. 
 
   106:    Gly-Met-Ala-Ser-Lys-Ala-Gly-Ala-20-Ala-Gly-Lys-Ile-Ala-Lys-Val-Ala-Leu-Lys-Ala-Leu-NH2 
   107:    Gly-Met-Ala-Ser-Lys-Ala-Gly-Ala-Ile- 20 -Gly-Lys-Ile-Ala-Lys-Val-Ala-Leu-Lys-Ala-Leu-NH2 
   108:    Gly-Met-Ala-Ser-Lys-Ala-Gly-Ala-Ile-Ala-Gly-Lys-20-Ala-Lys-Val-Ala-Leu-Lys-Ala-Leu-NH2 
   109:    Gly-Met-Ala-Ser-Lys-Ala-Gly-Ala-Ile-Ala-Gly-Lys-Ile- 20 -Lys-Val-Ala-Leu-Lys-Ala-Leu-NH2 
 
Fig. 5.7. Amino acid sequences of CF3-labelled analogues of PGLa, 106-109. 
 
The amino acid 20 was easily incorporated into the peptides by using the standard 
activators HCTU/HOBt. Moreover, this process effectively occurred with the use of 
only a double excess of Fmoc-derivative 101.* The amino acids next to the 19F-label 
20 were incorporated without difficulties as well. All HPLC chromatograms of crude 
106-109 mixtures contained only one major peak, thus indicating that 20 did not 
racemize during the synthesis.† Here again, similar to the synthesis of 100, the new 
19F-label 20 appeared to be completely compatible with the standard techniques of 
SPPS. 
                                                 
* Incorporation of the natural amino acids was performed using a fourfold excess of the corresponding Fmoc-derivatives. 
† Analysis of minor peaks by MALDI-TOF revealed that they had masses different from that of the target peptide. 
Gly-Met-Ala-Ser-Lys-Ala-Gly-Ala-Ile-Ala-Gly-Lys-Ile-Ala-Lys-Val-Ala-Leu-Lys-Ala-Leu-NH2
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5.2.3. Influence of CF3-Bpg on the conformation of PGLa 
 
To evaluate the potential influence of the 19F-label 20 on the PGLa 
conformation, CD spectra of 106-109 and PGLa were measured in detergent micelles 
and compared.  
 
 
Fig. 5.8. CD spectra of PGLa  and 106-109 (30 µM) in water sodium dodecyl sulfate micelles (5 mM) at 20 °С. 
 
Fig. 5.8 demonstrates that the СD spectra of all peptides in water in the 
presence of SDS micelles are similar and correspond to an α-helical conformation. 
This means that incorporation of the 19F-label 20 into PGLa did not influence the 
membrane-bound conformation of PGLa. 
 
5.2.4. Influence of CF3-Bpg on the antimicrobial activity of PGLa 
 
After the synthesis of the PGLa analogues 106-109 and comparison of their 
conformational preferences, the antimicrobial activity of these peptides against 
several strains of Gram-positive and Gram-negative bacteria was evaluated (Table 
5.1). 
 
Table 5.1. Minimal inhibitory concentration (MIC, mg/ml) values* of PGLa and its analogues 106-109. 
 
strain  peptide  PGLa 106 107 108 109 
E.coli ATCC 25922 8 8 8 8 8 
E.coli DH5 4 4 4 4 4 
Acinetobacter sp. ATCC 33304 4 4 4 8 8 
S. aureus ATCC 25923 8 8 4 8 4 
B. subtilis ATCC 6633 4 4 2 4 4 
M. luteus ATCC10240 16 4 2 4 2 
K. rhizophila ATCC 9341 8 8 4 8 4 
 
* peptide concentration, at which bacterial growth is suppressed by 50%.  
-15 
-10 
 -5   
0 
5 
10 
15 
20 
25 
30 
200 190 200 210 220 230 240 250 260 
PGLa
106 
107 
108 
109 
θ (mdeg) 
 
λ (nm) 
  
58
Since the MIC values were similar for all peptides, the assay proved that the 
presence of the 19F-label 20 did not influence the antimicrobial activity of PGLa.222 
 
5.2.5 Influence of CF3-Bpg on the orientation of PGLa in lipid bilayers 
 
To evaluate further the potential of CF3-Bpg (20) as a 19F-label, solid state 19F-
NMR spectra of oriented samples containing 106-109, embedded in DMPC bilayers, 
were measured (Fig. 5.9). Two peptide/lipid (P/L) ratios of 1/200 and 1/50 were used, 
because under these conditions PGLa is known to adopt different orientations: a 
surface-aligned “S-state” at P/L = 1/200 (Fig. 5.10, a) and an obliquely tilted “T-
state” at P/L =1/50 (Fig. 5.10, b).80,223,224, 
 
 
 
Fig. 5.9. Solid state 19F-NMR spectra of 106-109, reconstituted into macroscopically oriented DMPC bilayers. Two 
peptide/lipid (mol/mol) ratios are compared: a) 1/200, corresponding to the surface-bound S-state; b) 1/50, 
corresponding to the tilted T-state. All samples were measured at 35 °C with the membrane normal parallel to the 
magnetic field. The measured dipole-dipole splittings are depicted in red and the corresponding coupling values are 
given. 
 
All peptides were well aligned, as there were no powder lineshapes seen, and 
the individually labelled positions obviously produced different spectra. Differences 
were also seen for the two peptide/lipid ratios, suggesting that the alignment of PGLa 
indeed differs in the two concentration regimes addressed here.  
From the collected four sets of orientational constraints (dipolar splittings) for 
each P/L ratio, the orientational parameters (ρ, τ and Smol) of PGLa were calculated. 
The results obtained here are compared with previous data acquired from four 4CF3-
Phg (4) labels attached to the very same positions in the peptide (Table 5.2). 
 
 
 
 
 
 
 
 
a) b) 
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Table 5.2. Numerical best-fit solutions for the structure and dynamics of PGLa in DMPC, obtained using the 
established label 4CF3-Phg (4) and the new CF3-Bpg (20). The number of constraints used and their positions in PGLa 
are indicated (RMSD: root mean square deviation between the experimental and calculated values of the spectral 
splittings). 
 
labels used labelled positions RMSD (kHz) Smol ρ (°) τ (°) 
P/L = 1/200 (S-state) 
4 × CF3-Bpg (20) Ile9, Ala10, Ile13, Ala14 0.2 0.68 116 98 
4 × 4CF3-Phg (4) Ile9, Ala10, Ile13, Ala14 0.5 0.60 112 97 
P/L = 1/50 (T-state) 
4 × CF3-Bpg (20) Ile9, Ala10, Ile13, Ala14 0.3 0.63 89 134 
4 × 4CF3-Phg (4) Ile9, Ala10, Ile13, Ala14 0.2 0.63 91 134 
 
As can be seen from Table 5.2, the values of τ, ρ and Smol obtained at both 
peptide concentrations are essentially the same, irrespective of which NMR labels are 
analyzed. At P/L = 1/200 the peptide possesses a surface-bound “S-state” (Fig. 5.10, 
a). Upon increasing the peptide concentration to 1/50, the change in tilt angle (τ) by 
over ~30° demonstrated that PGLa is flipped into the tilted “T-state” (Fig. 5.10, b). 
 
Fig. 5.10. Different orientations of PGLa embedded in a lipid bilayer: a) “S-state”; b) “T-state”.80,223,224 
 
 The results, obtained here on PGLa confirm the conclusions drawn in the 
previous section (Chapter 5.1), expand the range of experimentally tested substitution 
positions (Leu/20, Ile/20, Ala/20) and prove the full equivalency of the structural data 
obtained with the use of 20 compared to those acquired using the established 19F-
label 4CF3-Phg (4).  
 
 
5.3. Cell-penetrating peptide SAP 
 
5.3.1. General information about SAP 
 
SAP is a new synthetic cell-penetrating peptide developed in 2004 (Fig. 
5.11).225-229226227228229   
a) b) 
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Fig. 5.11. Structural model of  SAP in an ideal PP II conformation, and amino acid sequence of  SAP. 
 
SAP is a peptide prone to aggregation: in aqueous solution at concentrations 
above 50 µM it forms fibrils. The main conformation of SAP in water solution is a PP 
II helix.230 
Concerning the mechanism of cell penetration by SAP, it is 
postulated that, at least in HeLa cells, it occurs via receptor-
independent endocytosis.231,232 Interestingly, a substitution of Pro by 
more hydrophilic silano-Pro has been shown to cause a 20-fold 
increase in the cellular uptake of SAP.233 It is also important that, on the contrary to 
many other CPPs, SAP demonstrates very low toxicity to HeLa cells. The structure of 
SAP upon binding to biomembranes and during the process of cell-penetration is 
unknown. 
 
5.3.2. Synthesis of SAP and its СF3-labelled analogues 
 
For structural studies of SAP the new 19F-labels 20 and 51а were used. First, 
the Pro-derived amino acid 51а was converted into its Fmoc-derivative 110 (Scheme 
5.5). 
 
N
CF3
COOHN
H
CF3
COOH
Fmoc-Cl
NaHCO3
110
Fmoc
50а
(80%)
 
 
Scheme 5.5. Synthesis of 110. 
 
The 19F-label CF3Bpg (20) was incorporated into SAP at the positions 3 (Leu), 7 
(Val), 9 (Leu), 13 (Val) or 15 (Leu). 19F-label 51а was introduced instead of Pro at 11 
position of SAP (Fig. 5.12). 
 
              111:    Val-Arg- 20 -Pro-Pro-Pro-Val-Arg-Leu-Pro-Pro -Pro-Val-Arg-Leu-Pro-Pro-Pro 
              112:    Val-Arg-Leu-Pro-Pro-Pro- 20 -Arg-Leu-Pro-Pro -Pro-Val-Arg-Leu-Pro-Pro-Pro 
              113:    Val-Arg-Leu-Pro-Pro-Pro-Val-Arg- 20 -Pro-Pro -Pro-Val-Arg-Leu-Pro-Pro-Pro 
              114:    Val-Arg-Leu-Pro-Pro-Pro-Val-Arg-Leu-Pro-51a-Pro-Val-Arg-Leu-Pro-Pro-Pro 
              115:    Val-Arg-Leu-Pro-Pro-Pro-Val-Arg-Leu-Pro-Pro -Pro- 20 -Arg-Leu-Pro-Pro-Pro 
              116:    Val-Arg-Leu-Pro-Pro-Pro-Val-Arg-Leu-Pro-Pro -Pro-Val-Arg- 20 -Pro-Pro-Pro 
 
Fig. 5.12. Amino acid sequences of CF3-labelled SAP analogues of SAP 111-116. 
 
Val-Arg-Leu-Pro-Pro-Pro-Val-Arg-Leu-Pro-Pro-Pro-Val-Arg-Leu-Pro-Pro-Pro 
N
H
Si
COOH
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The synthesis of SAP was carried out manually, controlling each coupling step 
by МАLDI-TOF and analytical HPLC. This monitoring revealed that incorporation 
of Arg and the amino acid following the Arg (Val) into the peptide was not complete. 
However, after double coupling had been applied during the incorporation of Arg and 
Val, the crude SAP was obtained with a purity of > 95% (Fig. 5.13). 
 
(min)  
Fig. 5.13. HPLC chromatogram of manually synthesized SAP. Arg and Val were incorporated by using double 
coupling. 
 
 Synthesis of the CF3-labelled SAP analogues 111-116 was performed 
analogously to SAP. During the synthesis of 114 it was found that amino group of 
51а, when incorporated in the peptide, had a reduced reactivity. However, by 
increasing the reaction time, coupling of the next amino acid (Pro) occurred 
completely. HPLC of all reaction mixtures 111-116 showed a single peak, thus 
suggesting that neither 20 nor 51a had racemized during synthesis. 
 
5.3.3. Influence of CF3-Bpg and CF3-MePro on the conformation of SAP  
 
In order to clarify  whether incorporation of the new 19F-labels 20 and 51a 
influences the conformation of SAP, CD spectra of 111-116 were acquired and 
compared with those of native SAP (Fig. 5.14). 
 
 
Fig. 5.14. CD spectra of SAP and 111-116 (10 µM) in 10 mM buffer NaH2PO4/Na2HPO4 at 20 °С.  
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As can be seen from the Fig. 5.14, 19F-label 20 did not perturb the PP II 
conformation of SAP, since СD spectra of 111-113, 115, 116 and SAP are almost 
identical. 19F-label 51а, on the contrary to 20, appears to stabilize the PP II 
conformation, since the bands at 203 and 223 nm in the spectrum of 114 have 
significantly higher intensity than the corresponding signals in all other peptides. 
 A major obstacle in quantifying the formation of PP II helix by CD is its close 
resemblance to the random coil conformation. To properly quantify the PP II 
contribution, spectral data has to be acquired down to 178 nm,53 which is 
experimentally a challenging task. However, semiquantitative data for a random 
coil/PP II equilibrium can be obtained from temperature dependent measurements. 
The results of such temperature series for SAP, 113 and 114 are shown in Fig. 5.15. 
Since the CD spectra of each peptide at different temperatures have only one 
isodichroic point, the equilibrium between the two conformations (random coil and 
PP II) exists for all tested peptides. Interestingly, 114 reveals a higher amount of PP 
II assembled molecules, since the positive intensity of the signal at 223 nm persists 
even at 50 °C.  
 
 
Fig. 5.15. CD spectra of SAP, 113 and 114 (10 µM) in 10 mM buffer NaH2PO4/Na2HPO4 (pH = 7.4) at temperatures 
10-50 °С (changed in steps of 5 °С). For each peptide the isodichroic point is indicated by a black dot. 
 
 To examine the propensity of SAP, 113 and 114 to self-assemble into 
aggregates, the СD spectra were measured over a concentration range of 5-150 µM. 
SAP and 113 exhibit spectral changes up to 50 µM, which for SAP was shown in the 
literature to reflect oligomerization (fibril formation)230 beyond this point (Fig. 5.16). 
50 °C  
10 °C 
260 200 220 240 
-8 
-6 
-4 
-2 
0 
190 210 230 250 
SAP 
λ (nm)
θ (mdeg) 
50 °C
10 °C 
260 200 220 240 
-8 
-6 
-4 
-2 
0
190 210 230 250 
113 
λ (nm)
θ (mdeg) 
50 °C 
10 °C 
260 200 220 240 190 210 230 250 
114 
-10 
-5 
0 
-7.5 
-2.5 
θ (mdeg) 
λ (nm)
  
63
In contrast, 114 oligomerized only at a concentration twice as high (100 µM), which 
might be a result of an increased PP II population. 
 
 
 
Fig. 5.16. CD spectra of SAP, 113 and 114 over a concentration range (5-150 µM) where oligomerization is expected. 
The spectra were measured in 10 mM NaH2PO4/Na2HPO4 buffer at 20 °C. 
 
All the CD data confirmed that 20 does not change the conformational 
behaviour of SAP, whereas 51a seems to stabilize the PP II conformation of SAP.  
 
5.3.4. Solid state 19F-NMR studies of  SAP in lipid bilayers  
 
To study the structure of SAP upon binding to biomembrane, solid state 19F-
NMR spectra of 111-116 in lipid bilayers were measured. The lipid DMPC was used 
first, as it is known to orient well and is one of the most popular biomembrane 
models. It has a lipid phase transition temperature of Tc = 24 °C and therefore 
provides a convenient system to access both gel and liquid crystalline states.234 All 
19F-labelled SAP-analogues were reconstituted and measured in the temperature 
range of 15-55 °C. Fig. 5.17 shows a representative temperature series from the 
sample containing 116 at P/L of 1/50. All other peptides, including 114, showed 
virtually the same temperature dependent spectral changes at both P/L = 1/50 and 
1/200 (and are therefore not shown). At low temperatures (gel state of lipids) the 
solid state 19F-NMR spectra predominantly contained quasi-isotropic singlets. At 
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higher temperatures (above Tc of DMPC), additional signals appeared reversibly at 
the cost of the quasi-isotropic signals (liquid crystalline state of lipids). Therefore, 
SAP seems to have different modes of interaction (orientation and/or structure) with 
the zwitterionic DMPC bilayers below (“isotropic” state of SAP) and above Tc 
(“ordered” state of SAP).  
 
 
 
Fig. 5.17.  Solid state 19F-NMR spectra of 116 over a temperature range 15-55 °C (changed in steps of 5 °С). 
Peptide/DMPC = 1/50 (mol/mol).  
 
Both “isotropic” and “ordered” states were observed for all peptides also in POPC 
and DMPC/DMPG (3/1, mol/mol) bilayers (data not shown), suggesting neither the 
type of lipid chain nor the presence of negatively charged lipids affects this general 
behaviour of the cationic peptide. It should be noted that the kinetics of the transition 
between the two SAP states appear to be rather slow, since different equilibration 
times (10 min, 0.5 h, 4 h, 12 h, 24 h) produced different proportions of the molecules 
in the different states. At high temperature (55 °C) using a prolonged equilibration 
time (12 h), a pure “ordered” state was observed (Fig. 5.18). In all cases, however, 
the spectral appearance was rather complex and the coexistence of 2-3 triplets was 
evident (Fig. 5.18). This means that under the abovementioned conditions SAP 
possesses several orientations (assuming that one splitting corresponds to one 
particular orientation or conformation). The calculation of all these structures is a 
considerable challenge, since the signals are significantly overlapped and therefore an 
extraction of the corresponding dipole-dipole constants is hindered. An experimental 
solution of this problem is currently in progress (i.e. different multipulse experiments 
to separate and assign the individual splittings). 
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Fig. 5.18. Solid state 19F-NMR spectra of 111-116 at 55 °C. Peptide/lipid = 1/50. Lipids: DMPC/DMPG = 3/1. Before 
measurement each sample was pre-equilibrated at the corresponding temperature for 12 h. Dominant dipole-dipole 
splittings are depicted in red, the corresponding values of dipole-dipole constants being given above the signals. For the 
peptide 114 all the constants are shown (depicted in blue and green). 
 
In the extensively equilibrated “ordered state”, nevertheless, all peptides 
labelled with CF3-Bpg (111, 112, 113, 115, 116) show one predominent splitting 
among others (Fig. 5.18). Therefore, from the collected sets of orientational 
constraints, the compatibility of SAP structure with various helical conformations (PP 
II, 310-helix, π-helix, α-helix) was tested (Table 5.3).  
 
Table 5.3. Numerical best-fit solutions for the structure of SAP modeled as a PP II helix, 310-helix, π-helix or an α-
helix. The dipole-dipole splittings from the dominant triplets in the peptides 111, 112, 113, 115, 116 were used for 
calculations. (RMSD: root mean square deviation between the experimental and calculated values of the spectral 
splittings). 
 
conformation RMSD (kHz) Smol τ (°) ρ (°) 
PP II 0.77 1.0 83 139 
310-helix 1.94 1.0 91 35 
π-helix > 4.8 - - - 
α-helix > 7.3 - - - 
 
From the Table 5.3 it can be seen that the minimal RMSD value is observed for 
the PP II conformation, with ρ = ~139°, τ = ~83° and Smol = ~1.0. In order to clarify 
whether the peptide 114 with the as yet unexplored Pro-derived 19F-label (51a) meets 
this solution as well, all splittings present in solid state 19F-NMR spectrum of 114 
(Fig. 5.18) were included one by one in this calculation. The calculation confirmed 
that one constant (-4.1 kHz) among the three possibilities does indeed fit to the 
obtained solution.  
Thus, one state of SAP (among others) in the model membranes corresponds to 
the PP II conformation under the experimental conditions tested (55 °C; 
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DMPC/DMPG = 3/1, P/L = 1/50). The peptide is aligned parallel to the lipid bilayer 
surface (τ = 83°), the lipophilic residues of Val and Leu are pointing towards the 
interior and the hydrophilic residues of Arg out of the lipid bilayer (ρ = 139°) (Fig. 
5.19). The observation that there is no wobbling (Smol = 1.0) suggests that the peptide 
is in an oligomeric state. 
 
 
 
Fig. 5.19. SAP orientation in a lipid bilayer (SAP/lipid = 1/50; DMPC/DMPG = 3/1) at 55 °C.  
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PART 6 
EXPERIMENTAL PART 
 
All air- and moisture-sensitive reactions were performed under an argon 
atmosphere using standard Schlenk technique. Solvents were purified according to 
standard procedures.235 All starting materials, which are not described in the 
experimental part, were purchased from Acros, Merck, Enamine and Fluka. Melting 
points are uncorrected. Analytical TLC was performed using Polychrom SiF254 plates. 
1H-, 13C- and 19F-NMR spectra were recorded either on a Varian Unity Plus 400 
spectrometer (at 400, 101 and 377 МНz respectively) or on a Bruker Avance 500 
spectrometer (at 500 MHz, 125 and 470 MHz). Chemical shifts are reported in ppm 
downfield from TMS (1H, 13C) or C6F6 (19F) as internal standards. IR spectra were 
obtained on a Hewlett Packard UR 20 spectrometer. The νmax (cm-1) values of the IR 
spectra are given for the main absorption bands. Mass spectra were recorded either on 
an Agilent 1100 LCMSD SL instrument by chemical ionization (CI), or on a Bruker 
Biflex IV instrument (MALDI-TOF). MALDI samples were co-crystallized with a 
matrix of 3,5-dihydroxy-benzoic acid from acetonitrile/water solutions onto a 
stainless steel target. Elemental analysis: Microanalytic Laboratory, Institute of 
Organic Chemistry, University of Karlsruhe. Optical rotation values were measured 
on a PerkinElmer 341 polarimeter. 
 
1-Iodo-3-(trifluoromethyl)-bicyclo[1.1.1]pentane, 26 
16.53 g (55.7 mmol) 25 and 40 ml of absolute pentane were placed in a 
Favorsky flask. To this suspension cooled to -78 ºС 1.6М solution of MeLi in Et2O 
(99 ml) was added dropwise over 20 min. The cooling was stopped; the mixture was 
allowed to warm to 0 °С and stirred for 1 h at this temperature. Thereafter, mixture of 
Et2O, pentane and propellane was distilled under reduced pressure into an ampule 
cooled by liquid nitrogen. Favorsky flask was disconnected and 10.9 g (55.7 mmol) 
CF3I was froze into the ampule. The ampule was closed and leaved in a safety place 
for 3 days. Evaporation of the solvent at 0 ºС (the product is very volatile) gave 26 
(9.05 g, 34.5 mmol, 62%) as a white crystals.  
1Н-NMR (400 MHz, DMSО-D6): 2.52 (s). 
19F-NMR (377 MHz, DMSО-D6): 95.87 (s). 
The obtained product has to be immediately used in the next step, otherwise it must 
be purified by sublimation prior to the use (at 0 ºС under an argon atmosphere 
decomposition of 26 occurs completely in one week). 
 
3-(Trifluoromethyl)bicyclo[1.1.1]pentane-1-carbaldehyde, 27 
Methoxy[3-(trifluoromethyl)bicyclo[1.1.1]pent-1-yl]methanol, 28 
A solution of t-BuLi in Et2O (2.0 ml of 
1.6 M, 3.2 mmol) was added dropwise to a 
stirred solution of 26 (424 mg, 1.6 mmol) in 
Et2O (10 ml) at -78 ºC. The addition was completed in 10 min, and the mixture was 
stirred for additional 30 min at -78 ºC. This mixture, cooled to -78 ºC, was added 
dropwise to a stirred solution of HCO2Me (0.40 ml, 6.8 mmol) in Et2O (15 ml) at -78 
CF3
O
H
CF3
OH
OMe
+
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ºC over 10 min. Once the addition had been completed, the stirred mixture was 
allowed to warm to room temperature. After extraction with H2O (3 × 10 ml) the 
water phase was discarded. The organic layer was separated, dried over MgSO4 and 
concentrated in vacuum at 0 ºC to ~10 ml (the products are very volatile!). The 
resulting solution of 27 and 28 in Et2O was used in the next step without further 
purification. 
For the synthesis of individual compounds the obtained solution was 
evaporated at 0 ºС under reduced pressure. Yellowish oil. Ratio 27/28 is ~2/1. 
1Н-NMR (400 MHz, СDСl3): 9.61 (s, 1H, CHO from 27); 4.51 (s, 1H, CH from 28); 
3.41 (s, 3H, OCH3 from 28); 2.25 (s, 6H, CH2 from 27); 1.90 (s, 6H, CH2 from 28). 
19F-NMR (377 MHz, СDСl3): 88.24 (s, CF3 from 27); 88.48 (s, CF3 from 28). 
After addition of several drops of MeOH into NMR-tube, both 1Н- and 19F-NMR 
spectra contained only signals of hemiacetale 28. 
 
2(S)-{[(1R)-2-Hydroxy-1-phenylethyl]amino}-2-[3-(trifluoromethyl)bicyclo 
[1.1.1]pent-1-yl]acetonitriles, 30 
2(R)-{[(1R)-2-Hydroxy-1-phenylethyl]amino}-2-[3-(trifluoromethyl)bicyclo 
[1.1.1] pent-1-yl]acetonitriles, 29 
A solution of (R)-2-phenylglycinol (222 mg, 1.6 mmol) in MeOH (20 ml) was 
added to the solution of 27 and 28 in Et2O (10 ml), obtained in the previous step, and 
the resulting mixture was stirred for 2 h at room temperature. After cooling to 0 ºC, 
Me3SiCN (634 mg, 6.4 mmol) was added, and the resulting mixture was stirred at 
room temperature for 10 h. Evaporation of the solvent in vacuum gave a residue, 
which was submitted to column chromatography. Elution with hexane/EtOAc = 3/2 
afforded 30 first (244 mg, 0.78 mmol, 53%) as a colorless solid. Rf = 0.7. Crystals for 
X-ray analysis were obtained by crystallization from hexane. M.p. = 99-100 ºC. 
[α] 20D  = -133.1 (c = 0.26 mg/ml, MeOH). 
1Н-NMR (400 MHz, СDСl3): 7.38-7.30 (m, 5H, Ph); 4.80 (dd, 
3J(H, H) = 9.6, 4.0 Hz, 1H, CHCH2); 3.80 (dd, 2,3J(H, H) = 
10.4, 4.0 Hz, 1H, CHCH2); 3.58 (dd, 2,3J(H, H) = 10.4, 9.6 Hz, 
1H, CHCH2); 3.42 (s, 1H, CHCN); 2.35 (bs, 2H, OH+NH); 
2.06-2.00 (2 d, 2J(Н, Н) = 9.6 Hz, 6Н, CH2).  
19F-NMR (377 MHz, СDСl3): 88.66 (s, CF3). 
13C-NMR (101 MHz, СDСl3): 137.97 (s, ipso-C, Ph); 129.21 (s, CH, Ph); 128.73 (s, 
CH, Ph); 127.27 (s, CH, Ph); 122.65 (q, CF3, 1J(C, F) = 274 Hz); 117.86 (s, CN); 
67.53 (s, CHPh); 63.19 (s, CH2OH); 48.67 (bs, CH2); 47.52 (q, CHCN, 5J(C, F) = 2 
Hz); 38.87 (s, CH2CCH); 37.40 (q, CF3C, 2J (C, F) = 40 Hz). 
IR (КBr): 2232 (ν C≡N), 1175 (ν C-O) cm-1. 
MS (m/z): 311.2 (M)+. 
Further elution with the same solvent yielded 29 (202 mg, 0.62 
mmol, 40%) as a colorless solid. Rf = 0.65. Analytically pure 
sample was obtained by crystallization from hexane. M.p. = 
101-102 ºC. [α] 20D  = -21.4 (c = 0.25 mg/ml, MeOH). 
CF3
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1Н-NMR (400 MHz, СDСl3): 7.34-7.26 (m, 5H, Ph); 4.00 (s, 1H, CHCN); 3.92 (dd, 
3J(H, H) = 8.0, 4.0 Hz, 1H, CHCH2); 3.72 (2,3J(H, H) = 11.2, 4.0 Hz, 1H, CHCH2); 
3.63 (dd, 2,3J(H, H) = 11.2, 8.0 Hz, 1H, CHCH2); 3.2-2.3 (bs, 2H, OH+NH); 2.00-
1.95 (2 d, 2J(Н, Н) = 9.6 Hz, 6H, CH2). 
19F-NMR (377 MHz, СDСl3): 88.64 (s, CF3). 
13C-NMR (101 MHz, DMSO-D6): 141.64 (s, ipso-C, Ph); 128.71 (s, CH, Ph); 128.22 
(s, CH, Ph); 127.87 (s, CH, Ph); 122.83 (q, CF3, 1J(C, F) = 274 Hz); 119.07 (s, CN); 
66.55 (s, CHPh); 63.75 (s, CH2); 49.19 (bs, CH2OH); 47.61 (q, CH(CN)N, 5J (C, F) = 
2 Hz); signal CH2-C-CH is hidden by the residual peak of DMSO-D6; 36.76 (q, 
CF3C, 2J(C, F) = 38 Hz). 
IR (KBr): 2240 (ν C≡N), 1172 (ν C-O) cm-1. 
MS (m/z): 311.2 (M)+, 284.4 (M - CH2OH)+, 282 (M - HCN)+. 
 
Isomerization of 2(R)-{[(1R)-2-hydroxy-1-phenylethyl]amino}-2-[3-
(trifluoromethyl)bicyclo[1.1.1] pent-1-yl]acetonitrile, 29 
Isomer 29 was refluxed in МеОН (~10 ml MeOH per 1 g of 29) for ~3 h. 
Evaporation of the solvent gave solid mixture of 29/30 (~1/4), which was separated 
by either column chromatography or crystallization: 
Separation of 29/30 by crystallization: 
1) Isomerized mixture 29/30 (~1/4) was crystallized from cyclohexane. 
2) The obtained mixture 29/30 (~1/5) was crystallized from CCl4 (6 ml CCl4 per 1 g 
of 29/30) to give pure 30. 
3) The mother liquids were collected, evaporated, isomerized in МеОН, and the 
formed mixture was separated by crystallization again. 
 
(2S)-2-Amino-2-[3-(trifluoromethyl)bicyclo[1.1.1]pent-1-yl]ethanoic acid, 
20 
Pb(OAc)4 (0.200 mg, 0.45 mmol) was added to a solution of 30 (100 mg, 0.32 
mmol) in CH2Cl2/MeOH (20 ml, 1/1) stirred at 0 ºC. After being 
stirred at this temperature for 5 min, the reaction was quenched 
with saturated aq. solution of NaHCO3 (5 ml). The resulting 
insoluble material was removed by filtration and washed with 
CH2Cl2 (10 ml). Organic layer was separated, and the aqueous layer was extracted 
with CH2Cl2 (2 × 15 ml). The combined organic phases were evaporated in vacuum 
to give the Schiff base 31 as yellow oil. It was dissolved in aq. HCl (6M, 20 ml) and 
refluxed for 2 h. After cooling, the reaction mixture was washed with Et2O (3 × 5 ml) 
and the aqueous layer was evaporated to produce a white solid. Afterwards, the 
residue was dissolved in H2O (~5 ml), neutralized with aq. NaOH (0.3M) and 
submitted to ion exchange resin chromatography (Dowex 50 × 400, cation-
exchange). Elution with water followed by aq. NH3 (10%) afforded 20 (63 mg, 0.30 
mmol, 95%) as a white solid. M.p. = 210-212 ºC. [α] 20D  = +14.0 (c = 0.84 mg/ml, 
H2O). 
1Н-NMR (400 MHz, D2О): 3.70 (s, 1H, CH); 1.94 (s, 6H, CH2).  
19F-NMR (377 MHz, D2О): 87.66 (s, CF3). 
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13C-NMR (101 MHz, D2О): 171.64 (s, COOH); 122.61 (q, CF3, 1J(C, F) = 274 Hz); 
54.71 (s, CH2); 47.75 (q, CH, 5J(C, F) = 2 Hz); 37.35 (q, CH2CCH, 4J(C, F) = 2 Hz); 
36.05 (q, CF3C, 2J(C, F) = 40 Hz). 
MS (m/z): 210 (M)+, 
Elemental analysis, calculated for C8H10F3NO2: C, 45.94; H, 4.82; N, 6.70. Found: C, 
45.78; H, 4.53; N, 6.59. 
 
(2R)-2-Amino-2-[3-(trifluoromethyl)bicyclo[1.1.1]pent-1-yl]ethanoic acid, 
36 
36 was synthesized from 29 analogous to 20. 
 
 
(1R)-Bicyclo[1.1.1]pentane-1-methanaminium, α-(methoxycarbonyl)-3-
(trifluoromethyl), chloride, 37*HCl 
A solution of 36 (35 mg, 0.17 mmol) in 0.25 ml МеОН 
was cooled to -20 ºС and treated with SOCl2 (27 µl). Cooling 
was stopped and the mixture was leaved to stir for 3 days at 
room temperature. Evaporation of the solvent gave 37*HCl as a 
white solid (43 mg, 0.17 mmоl, 100%). 
1Н-NMR (400 MHz, СD3OD): 4.31 (s, 1H, CH); 3.87 (s, 1H, OCH3); 2.15-2.09 (2 d, 
6H, CH2).  
19F-NMR (377 MHz, СD3OD): 90.89 (s, CF3). 
 
(1R)-Bicyclo[1.1.1]pentane-1-acetic acid, α-amino-3-(trifluoromethyl)-, 
methyl ester, 37 
NEt3.(15 mg) was added to a solution of 37*HCl (43 mg, 
0.17 mmol) in МеOH (0.5 ml). The suspension was diluted 
with Et2O (5 ml) and the formed NEt3*HCl was removed by 
filtration. Evaporation of the solvent from the mother liquid gave 37 as colorless oil 
(29 mg, 0.14 mmоl, 80%). 
1Н-NMR (400 MHz, СDСl3): 3.74 (s, 1H, OCH3); 3.63 (s, 1H, CH); 1.93 (s, 6H, 
CH2).  
 
(1S)-Bicyclo[1.1.1]pentane-1-methanaminium, α-(methoxycarbonyl)-3-
(trifluoromethyl), chloride, 38*HCl 
38*HCl was synthesized from 20 analogous to 37*HCl. 
 
 
(1S)-Bicyclo[1.1.1]pentane-1-acetic acid, α-amino-3-(trifluoromethyl), 
methyl ester, 38 
38 was synthesized from 38*HCl analogous to 37. 
 
 
Methyl (2S)-2-(acetamino)-2-[3-(trifluoromethyl)bicyclo[1.1.1]pent-1-yl] 
acetate, 41 
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NEt3 (39 mg, 0.39 mmol) and СH3COCl (17 mg, 0.22 
mmol) were added to a suspension of 38*HCl (50 mg, 0.19 
mmol) in dioxane (3 ml) at once. The mixture was stirred for 15 
min, diluted with water (2 ml) and extracted with СН2Сl2 (3 × 
10 ml). Organic phase was dried over MgSO4 and evaporated. Colorless solid (40 mg, 
0.15 mmol, 80%). 
1Н-NMR (400 MHz, СD3OD): 4.60 (s, 1H, CH); 3.74 (s, 3H, OCH3); 2.00-1.94 (m, 
9H, CH2 + CH3CO). 
19F-NMR (101 MHz, СD3OD): 87.29 (s, CF3). 
 
(2S)-2-(Acetylamino)-N-methyl-2-[3-(trifluoromethyl)bicyclo [1.1.1]pent-1-
yl]acetamide, 40 
A solution of 41 (40 mg, 0.15 mmol) in МеОН (3 ml) 
and 40% aq. МеNH2 (1 ml) was placed into a sealed tube and 
heated at 100 °С for 5 h. After evaporation of the solvent the 
residue was purified by flash column chromatography. 
Elution with СН2Сl2/МеОН = 9/1 produced 40 (8 mg, 0.03 mmol, 20%) first as a 
colorless solid. Rf = 0.7. 
1Н-NMR (400 MHz, СD3OD): 4.45 (s, 1H, CH); 2.73 (s, 3H, CH3NH); 2.00 (s, 3H, 
CH3CO); 1.94 (s, 6H, CH2).  
19F-NMR (377 MHz, СD3OD): 90.85 (s, CF3). 
Further elution afforded СH3СONHСH3 as a colorless solid. Rf = 0.6.  
1Н-NMR (400 MHz, СD3OD): 2.69 (s, 3H, CH3NH); 1.91 (s, 3H, CH3CO). 
 
3,4-Dihydro-5-[2,2,2-trifluoro-1-methoxy-1-[(trimethylsilyl)oxy]ethyl]-2H-
pyrrole, 55 
1-(3,4-Dihydro-2H-pyrrol-5-yl)-2,2,2-trifluoro-1-ethanone, 56 
NH4F (430 mg, 4,8 mmоl) was activated at 
120-130 °C in vacuum over 2 h. After cooling to 
room temperature a solution of 54 (600 mg 4,8 
mmol) in THF (40 ml) was added. Thereafter, to 
the formed suspension CF3SiMe3 (738 mg, 5.4 mmol) was added dropwise at -60 °C 
and the reaction was stirred at this temperature for additional 2 h. After warming to 
room temperature the mixture was diluted with water (40 ml), extracted with СН2Сl2 
(3 × 50 ml) and dried over MgSO4. Evaporation of the solvent afforded 720 mg of 
oily material. 
In GC-MS chromatogram of the obtained mixture 3 peaks were visible: 
1 peak, 56: 165 (M)+, 137 (M-CH2N)+, 96 (M-CF3)+, 69 (CF3)+, 68 (M-CF3CO)+.  
2 peak, 55: 254 (M-Me)+, 254 (M-CF3)+, 96,  73 (SiMe3)+. 
3 peak, unidentified compound: 195, 163, 128, 96. 
If the reaction mixture was quenched with 1M HCl (instead of H2O) 1H-NMR 
spectrum became significantly simpler and contained predominantly signals of 57. 
1H-NMR (400 MHz, CD3OD): 4.33-4.25 (m, 2H); 2.98-2.90 (m, 2H); 2,47-2,38 (m, 
2H).  
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Trimethyl[[tetrahydro-2-(trifluoromethyl)-2-furanyl]oxy]-silane, 58 
CsF (2.63 g, 17,3 mmol) was activated at 120-130 °C in vacuum 
over 2 h. After cooling to room temperature a solution of γ-
butyrolactone (20.8 g, 220 mmol) in THF (80 ml) was added. The 
resulting suspension was cooled to -10 °C, and CF3SiMe3 (37.5 g, 264 mmоl) was 
added dropwise afterwards. The cooling was stopped and the mixture was stirred for 
20 h at room temperature. CsF was filtered off, solvent was evaporated and the 
residue was distilled (20 mm, 55-65 °C) to produce 57 (36.7 g, 74%). 
1H-NMR (400 MHz, CDCl3): 4.17-4.11 (m, 1H, 4-CH2); 3.94-3.86 (m, 1H, 4-CH2); 
2.28-2.20 (m, 1H, 3-CH2); 2.11-1.93 (m, 1H from 3-CH2 and 2H from 4-CH2); 0.14 
(s, 9H, Si(CH3)3). 
19F-NMR (377 MHz, CDCl3): 78.52 (s, CF3). 
 
1-Bromo-5,5,5-reifluoropentane-4-on, 57 
To the solution, obtained after dissolving Zn (27 mg, 0,4 
mmоl) in 48% aq. HBr (10 ml), 58 (4.5 g, 20 mmоl) was added. 
The mixture was refluxed over 78 h, cooled, diluted with water and 
extracted with EtOAc. Organic phase was dried over MgSO4, concentrated and 
redistilled in vacuum (20 mm, 65-75 °C). Colorless liquid (1.7 g, 3 mmo1, 15%). 
1H-NMR (400 MHz, CDCl3): 3.46 (t, 3J(Н, Н) = 6.0 Hz, 2H, CH2Br); 2.94 (t, 3J(Н, 
Н) = 6.8 Hz, 2H, C(O)CH2); 2.23 (m, 2H, CH2CH2Br). 
19F-NMR (377 MHz, CDCl3): 82.64 (s, CF3). 
 
(2RS)-1-[(1S)-1-Phenylethyl]-2-(trifluoromethyl)pirrolidine-carbonitrile, 
61(а,b) 
1-[2-(Trifluoromethyl)tetrahydrofuran-2-yl]acetone, 62 
Aminonitrile 60 (0.62 g, 3.3 mmol) was added to a solution of 57 
(0,65 g, 3.0 mmol) in CH3CN (5 ml). The mixture obtained was refluxed 
for 12 h, then poured into excess of 10% sodium hydroxide solution and 
extracted with dichloromethane. The combined extracts were dried 
(MgSO4) and evaporated under reduced pressure. The residue was purified (eluent - 
hexane/EtOAc = 20/1) by flash column chromatography to produce 61а (7 mg, 0.03 
mmоl, 1%) first (configuration is not confirmed). Rf = 0.60. 
1H-NMR (400 MHz, CDСl3): 7.13-7.24 (m, 5H, Ph); 4.44 (q, 3J(H, H) = 6.8 Hz, 1H, 
CHCH3); 2.89 (q, 3J(H, H) = 7.2 Hz, 1H, 5-CH2); 2.75 (m, 1H, 5-CH2); 2.39 and 2.32 
(m, 2H, 3-CH2); 1.78 (m, 2H, 4-CH2); 1.49 (d, 3J(H, H) = 6.8 Hz, 3H, CHCH3). 
19F-NMR (377 MHz, CDCl3): 84.6 (s, CF3). 
13C-NMR (101 MHz, CDCl3): 143.2 (s, ipso-С, Ph); 131.0 (q, 1J(C, F) = 252 Hz, 
CF3); 128.3 (s, CН, Ph); 126.9 (s, CН, Ph); 126.5 (s, CН, Ph); 117.2 (s, CN); 68.2 (s, 
2-C); 55.5 (s, CHCH3); 45.3 (s, 5-CH2); 35.7 (s, 3-CH2); 23.0 (CH3); 14.7(s, 4-CH2).  
IR (neat): 2232 (ν С≡N) cm-1. 
MS (m/z): 268 (M)+, 105 (PhCHCH3)+. 
Next fraction was a mixture of 61а/61b = 0.8/1. Rf  = 0.57. 
1H-NMR (400 MHz, CDСl3): 7.24-7.13 (m, 5H, Ph from 61a and 5H, Ph from 61b); 
4.44 3J(H, H) = 6.8 Hz, 1H, CHCH3 from 61a); 4.30 (q, 3J(H, H) = 6.8 Hz, 1H, 
O
CF3
OSiMe3
CF3
Br
O
N
CF3
CN
Ph
  
73
CHCH3 from 61b); 3.31 (m, 1H, 5-CH2, from 61b); 2.89 (m, 1H, 5-CH2 from 61a and 
1H, 5-CH2 from 61b); 2.75 (m, 1H, 5-CH2 from 61a); 2.31-2.39 (m, 2H, 3-CH2 from 
61a and 2H, 3-CH2 from 61b); 1.90 (m, 1H, 4-CH2 from 61b); 1.78-1.65 (m, 2H, 4-
CH2 from 61a and 1H, 4-CH2 from 61b); 1.49 (d, 3J(H, H) = 6.8 Hz, 3H, CHCH3 
from 61a); 1.37 (d, 3J(H, H) = 6.8 Hz, 3H, CHCH3 from 61b). 
19F-NMR (377 MHz, CDCl3): 85.1 (s, CF3 from 61b); 84.6 (s, CF3 from 61a). 
Third fraction: 62 (20 mg, 0.15 mmol, 5%). Rf  = 0.30. 
1H-NMR (400 MHz, CDCl3): 3.85 (d, J = 7.2 Hz, 2H, OCH2); 2.88 (d, 
2J(Н, Н) = 14.4 Hz, 1H, CH2CO); 2.41 (d, 2J(Н, Н) = 14.4 Hz, 1H, 
CH2CO); 2.34 (m, 1H); 2.11 (s, 3H, CH3); 2.05 (m, 1H); 1.94 (m, 2H).  
19F-NMR (377 MHz, CDCl3): 84.7 (s, CF3). 
13C-NMR (101 MHz, CDCl3): 201.2 (s, C=O); 124.6 (q, 1J(C, F) = 281.5 Hz, CF3); 
81.9 (q, 2J(C, F) = 27.6 Hz, CCF3); 69.2 (OCH2); 43.2 (s, CH2); 31.1 (CH3); 28.5 (s, 
CH2); 24.6 (s, CH2).  
IR (neat): 1716 (ν С=О) cm-1. 
MS (m/z): 127 (M-CF3)+, 69 (CF3)+, 43 (СН3СО)+. 
 
Cyclopropanation of 75-79. General procedure 
Diazotrifluoroethane, obtained in a generator flask by reaction of 
CF3CH2NH2*HCl (1 eq) with NaNO2 (1 eq), was gradually blown off by an inert gas 
through a drying tube (MgSO4) into a vessel equipped with a condenser. The vessel 
contained a stirring mixture of alkene and the catalyst (10 mol %) (in the case of 79, 
CH2Cl2 was used as a solvent). The mixture Ar/СF3СHN2 was blowing through an 
inlet in such a way, that it passed through the stirring mixture. To achieve a full 
reaction conversion a large excess of CF3CHN2 was used. Otherwise, the starting 
material could be removed by treating the mixture with acidic (pH ~5) 5% aq. 
KMnO4 solution and subsequent extraction of the cyclopropane derivatives with 
CH2Cl2.  
The products 75-78(а,b) were isolated by distillation, and afterwards isomers 
75(а,b) and 76(а,b) were separated by flash column chromatography. High volatility 
of 77(а,b) and 78(а,b) hindered their preparative separation. Products 79(а,b) were 
isolated chromatographically. 
 
1-[(1SR,2SR)-2-(Trifluoromethyl)cyclopropyl]benzene, (±)75a 
1-[(1RS,2SR)-2-(Trifluoromethyl)cyclopropyl]benzene, (±)75b 
Catalyst - Rh2(ОAc)4. B.p. of the mixture (±)75(a,b) = 75-80 ºC (20 mm). 
75a/75b = 2/1. 
(±)75а: Rf  = 0.7 in pentane/Et2O = 2/1. 
1Н-NMR (400 MHz, CDСl3): 7.32 (t, 3J(H, Н) = 7.6 Hz, 2H, Ph); 7.25 
(t, 3J(H, Н) = 7.6 Hz, 1H, Ph); 7.16 (d, 3J(H, Н) = 7.6 Hz, 2H, Ph); 2.44 
(dt, 3J(H, Н) = 9.2 Hz, 1H, PhCH); 1.87 (m, 1H, CF3CH); 1.46 (dt, 
2,3J(H, Н) = 9.6, 5.6 Hz, 1H, CH2); 1.25 (m, 1H, CH2). 
19F-NMR (377 MHz, СDСl3): 94.92 (d, 3J(H, F) = 7.5 Hz, CF3). 
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13C-NMR (101 MHz, CDСl3): 139.24 (s, ipso-С, Ph); 129.64 (s, СН, Ph); 128.82 (s, 
СН, Ph); 128.35 (s, СН, Ph); 123.68 (q, 1J(C, F) = 220.5 Hz, CF3); 23.14 (q, 2J(C, F) 
= 37.3 Hz, CF3CH); 19.78 (q, 3J(C, F) = 3.2 Hz, PhCH); 11.06 (q, 3J(C, F) = 3.2 Hz, 
CH2). 
MS (m/z): 206 (M)+. 
(±)75b: Rf  = 0.5 (pentane/Et2O = 2/1). 
1Н-NMR (400 MHz, CDСl3): 7.33 (d, 3J(H, Н) = 4.4 Hz, 4H, Ph); 7.27 
(m, 1H, Ph); 2.54 (dt, 3J(H, Н) = 8.4, 8.0 Hz, 1H, PhCH); 1.91 (m, 1H, 
CF3CH); 1.51 (dd, 2,3J(H, Н) = 7.2, 5.6 Hz, 1H, CH2); 1.35 (m, 1H, CH2). 
19F-NMR (377 MHz, СDСl3): 100.59 (d, 3J(H, F) = 7.5 Hz, CF3). 
13C-NMR (101 MHz, CDСl3): 135.49 (s, Ph); 133.10 (q, 1J(C, F) = 221.5 Hz, CF3); 
127.14 (s, Ph); 126.99 (s, Ph); 126.71 (s, Ph); 20.71 (q, 3J(C, F) = 3.2 Hz, Ph-CH); 
20.45 (q, 2J(C, F) = 35.2  Hz, CF3CH); 6.63 (q, 3J(C, F) = 3.2  Hz, CH2). 
MS (m/z): 206 (M)+. 
 
(1RS,6RS,7RS)-7-(Trifluoromethyl)-2-oxabicyclo[4.1.0]heptane,(±)76a 
(1SR,6SR,7RS)-7-(Trifluoromethyl)-2-oxabicyclo[4.1.0]heptane, (±)76b 
Catalyst - Rh2(ОAc)4. B.p. of the mixture (±)76(a,b) = 50-55 °C (20 mm). 
76a/76b = 2/1. 
(±)76а: Rf  = 0.8 in pentane/Et2O = 2/1.  
1Н-NMR (400 MHz, CDСl3): 3.72 (dd, 3J(H, Н) = 7.6, 2.0 Hz, 1H, 1-
CH); 3.57 (dtd, 2,3J(H, Н) = 11.2, 3.2, 1.2 Hz, 1H, 3-CH2); 3.28 (td, 
2,3J(H, Н) = 11.2, 1.6 Hz, 1H, 3-CH2); 2.06 (dd, 2,3J(H, Н) = 14.0, 4.8 
Hz, 1H, 5-CH2); 1.98 (m, 1H, 5-CH2); 1.55 (m, 2H, 4-CH2 and 6-CH); 1.44 (m, 2H, 
4-CH2 and 7-CH). 
19F-NMR (377 MHz, СDСl3): 96.61 (d, 3J(H, F) = 7.5 Hz, CF3). 
13C-NMR (101 MHz, СDСl3): 125.20 (q, 1J(C, F) = 270.4 Hz, CF3); 64.08 (s, 3-CH2); 
53.02 (q, 3J(C, F) = 2.5 Hz, 1-CH); 25.24 (q, 2J(C, F) = 35.2  Hz, 7-CH); 21.83 (s, 5-
CH2); 20.32 (s, 4-CH2); 14.89 (s, 6-CH). 
MS (m/z): 166 (M)+. 
(±)76b: Rf  = 0.6 pentane/Et2O = 2/1. 
1Н-NMR (400 MHz, CDСl3): 3.70 (m, 2H, 1-CH and 3-CH2); 3.29 (td, 
2,3J(H, Н) = 11.4, 2.0 Hz, 1H, 3-CH2); 2.06 (m, 2H, 5-CH2); 1.73 (m, 
1H, 4-CH2); 1.46 (m, 1H, 4-CH2); 1.28 (m, 2H, 6-CH and 7-CH). 
19F-NMR (377 MHz, СDСl3): 106.27 (d, 3J(H, F) = 7.5 Hz, CF3). 
13C-NMR (101 MHz, СDСl3): 126.00 (q, 1J(C, F) = 270.4 Hz, CF3); 64.19 (s, 3-CH2); 
51.91 (bs, 1-CH); 22.40 (q, 2J(C, F) = 35.2 Hz, 7-CH); 20.25 (s, 5-CH2); 14.17 (s, 4-
CH2); 12.49 (s, 6-CH). 
MS (m/z): 166 (M)+. 
 
2-(Trifluoromethyl)cyclopropylacetate, (±)77(a,b) 
Catalyst - Rh2(ОAc)4. B.p. of the mixture (±)77(a,b) = 60-70 °C (200 mm). 
77a/77b = 1.8/1.0. 
1Н-NMR (400 MHz, CDСl3): 4.40 (m, 1H, 1-CH from 
77а and 1H, 1-CH from 77b); 2.13 (s, 3H, CH3 from 
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77b); 2.10 (s, 3H, CH3 from 77a); 1.90 (m, 1H, 2-CH from 77a); 1.76 (m, 1H, 2-CH 
from 77b); 1.45-1.20 (m, 2H, 3-CH2 from 77а and 2H, 3-CH2 from 77b). 
19F-NMR (377 MHz, СDСl3): 100.84 (d, 3J(H, F) = 7.5 Hz, CF3 from 77b); 95.84 (d, 
3J(H, F) = 7.5 Hz, CF3 from 77a). 
13C-NMR (101 MHz, СDСl3): 170.09 (s, CH3COO from 77b); 169.59 (s, CH3COO 
from 77a); 125.12 (q, 1J(C, F) = 271.1 Hz, CF3 from 77b); 124.76 (q, 1J(C, F) = 270.1 
Hz, CF3 from 77a); 49.07-48.96 (2 overlapped q, 3J(C, F) = 4.0  Hz, O-CH); 20.10 (s, 
CH3 from 77a); 20.09 (s, CH3 from 77b); 19.95 (q, 2J(C, F) = 37.1  Hz, CCF3 from 
77a); 20.37 (q, 2J(C, F) = 36.1  Hz, CCF3 from 77b); 9.06 (q, 3J(C, F) = 3.1  Hz, CH2 
from 77a); 8.07 (q, 3J(C, F) = 3.1  Hz, CH2 from 77b). 
MS (m/z): 168 (M)+. 
 
7-(Trifluoromethyl)bicyclo [4.1.0]heptane, (±)78(a,b) 
Catalyst - CuOTf*0.5С6Н6. B.p. of the mixture (±)78(a,b) = 60-70 °C (100 
mm). 78a/78b = 2/1. 
1Н-NMR (400 MHz, CDСl3): 2.05-1.97 (m, 4H, CH2); 1.65-1.33 (m, 6H, CH2+CH); 
1.42-1.30 (m, 2H, 7-CH). 
19F-NMR (377 MHz, СDСl3): 100.57 (d, 3J(H, F) = 7.5 
Hz, CF3 from 78b); 95.59 (d, 3J(H, F) = 7.5 Hz, CF3 
from 78a). 
MS (m/z): 164 (M)+. 
 
Methyl (1RS,2RS)-1-(acetylamino)-2-(trifluoro-methyl)cyclopropane-
carboxylate, (±)79a 
Methyl (1RS,2SR)-1-(acetylamino)-2-(trifluoro-methyl)cyclopropane-
carboxylate, (±)79b 
The reaction was carried out in СH2Cl2. Catalyst Rh2(OAc)4. 
79a/79b = 1/1. 
(±)79а: Rf  = 0.4 in CH2Cl2/MeOH = 5/1.  
1Н-NMR (400 MHz, CDСl3, rotamers): 6.31 (2 bs, 1H, NH); 3.70 (2 s, 3H, OCH3); 
2.12 (m, 1H, CF3CH); 1.92 (2 s, 3H, CH3CO); 1.61 (m, 1H, СH2); 1.42 (m, 1H, СH2). 
19F-NMR (377 MHz, СDСl3): 101.41 (d, 3J(H, F) = 7.5 Hz, CF3). 
MS (m/z): 204 (M+1)+.  
(±)79b: Rf = 0.35 (CH2Cl2/MeOH = 5/1). 
1Н-NMR (400 MHz, CDСl3): 5.86 (bs, 1H, NH); 3.68 (s, 3H, OCH3); 
2.40 (m, 1H, CF3CH); 1.97 (bs, 4H, CH3CO and СH2); 1.68 (t, 2,3J(H, H) = 6.8 Hz, 
1H, СH2). 
19F-NMR (377 MHz, СDСl3): 100.07 (d, 3J(H, F) = 7.5 Hz, CF3). 
MS (m/z): 204 (M+1)+. 
 
 
(±)-Trifluoronorcoronamic acid hydrochloride, (±)82a 
A solution of (±)79а in 6M HCl was heated to 80 ºС over 
30 h (19F-NMR control). Evaporation of the solvent gave (±)82a 
as a white solid (quant.). 
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1Н-NMR (400 MHz, D2O): 2.35 (m, 1H, CF3CH); 2.92 (bs, 1H, CH2); 1.61 (bs, 1H, 
CH2).  
19F-NMR (377 MHz, CD3OD): 104.56 (d, 3J(H, F) = 7.5 Hz, CF3). 
MS (m/z): 170 (M-Cl)+. 
 
(±)-Trifluoro-allo-norcoronamic acid hydrochloride, (±)82b 
Compound (±)82b was synthesized from (±)79b analogous to (±)82а. 
1Н-NMR (400 MHz, D2O): 2.75 (m, 1H, CF3CH); 1.93 (t, 2,3J(H, 
H) = 9.2 Hz, 1H, CH2);  1.87 (t, 2,3J(H, H) = 9.2 Hz, 1H, CH2). 
19F-NMR (377 MHz, CD3OD): 102.33 (d, 3J(H, F) = 7.5 Hz, CF3). 
MS (m/z): 170 (M-Cl)+. 
 
2-Methyl 1-(2,2,2-trifluoroethyl) 2,5-dihydro-1H-pyrrole-1,2-
dicarboxylate, 83 
An excess of trifluoromethyldiazomethane, obtained in a 
generator flask by reaction of CF3CH2NH2*HCl with NaNO2 was 
gradually blown off by an inert gas through a drying tube (MgSO4) 
into a vessel, equipped with a condenser. The vessel contained a 
stirring solution of 72 (1.00 g, 4.41 mmоl) and anhydrous CuCl 
(500 mg) in hexane. The mixture Ar/СF3СHN2 was blowing through an inlet such a 
way, that it passed through a stirring solution. After 5 eq of CF3CH2NH2*HCl had 
been used, the reaction was stopped; the conversion of 72 was 30%. The mixture was 
diluted with CH2Cl2 and filtered. The filtrate was concentrated in vacuum and the 
residue was purified by flash chromatography. Elution with hexane/EtOAc = 10/1 
afforded starting material 72 first (Rf = 0.4 in hexane/EtOAc = 4/1) and then 83 (0.29 
g, 1.15 mmol, 26%) as a colorless viscous oil (Rf = 0.35 in hexane/EtOAc = 4/1). 
1Н-NMR (400 MHz, CDСl3, rotamers): 6.02 (m, 1H, 3-CH); 5.79 (m, 1H, 4-CH); 
5.03 (m, 1H, 2-CH); 4.60 (m, 1H, OCH2CF3); 4.37 (m, 3H, OCH2CF3 + 5-CH2); 3.77, 
3.74 (2 s, 3H, OCH3).  
19F-NMR (377 MHz, CDСl3, rotamers): 87.70, 87.52 (2 t, 3J(F, H) = 7.5 Hz, CF3). 
13C-NMR (126 MHz, CDСl3, rotamers): 170.02, 169.81 (2 s, COOCH3); 152.52, 
152.01 (2 s, NCO), 129.00, 128.78 (2 s, 3-CH); 125.22, 125.05 (2 s, 4-CH); 130.8 (q, 
1J(C, F) = 267.1 Hz, CF3); 66.74, 66.22 (2 s, 2-CH); 61.49, 61.36 (2 q, 2J(C, F) = 
37.8 and 35.2 Hz, OCH2CF3); 54.42, 53.53 (2 s, 5-CH2); 52.35 (s, OCH3). 
IR (neat): 1735 (ν C=O) cm-1.  
MS (m/z): 254 (M+1)+.  
 
2-Methyl 3-(2,2,2-trifluoroethyl) (1R,2S,5S,6R)-6-(trifluoromethyl)-3-
azabicyclo[3.1.0]hexane-2,3-dicarboxylate, 84a 
2-Methyl 3-(2,2,2-trifluoroethyl) (1S,2S,5R,6S)-6-(trifluoromethyl)-3-
azabicyclo[3.1.0]hexane-2,3-dicarboxylate, 84b 
An excess of СF3СHN2 (obtained as described above) was gradually blown off 
by an inert gas and passed through a drying tube (MgSO4) into a vessel containing a 
stirring mixture of 72 (4.00 g, 17.62 mmol) and CuOTf*0.5C6H6 (500 mg). The 
formed black tarry oil, consisted of 84a, 84b and side products, was dissolved in 
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CH2Cl2 and triturated with acidic (pH ~5) 5% aq. solution of KMnO4 (to remove 
compounds possessing C=C double bond). Water phase was separated and washed 
twice with CH2Cl2. Organic phases were combined, dried over MgSO4, and 
evaporated. The residue was dissolved in CH2Cl2/TFA (1/4) mixture and stirred for 2 
h (to remove compounds possessing Boc-groups). Finally, the solution was 
evaporated and the residue was purified by flash chromatography. Elution with 
hexane/EtOAc = 20/1 afforded 84a first (590 mg, 1.76 mmol, 10%) as a yellowish 
oil. Rf = 0.5 in hexane/EtOAc = 5/1. 
1Н-NMR (400 MHz, CDСl3, rotamers): 4.46 (m, 1H, OCH2CF3); 4.43, 4.42 (2 s, 1H, 
2-CH); 4.30 (m, 1H, OCH2CF3); 3.76 (m, 1H, 4-CH2); 3.74-3.72 (2 s, 3H, OCH3); 
3.71, 3.68 (2 d, 3J(H, H) = 4.0 Hz, 1H, 4-CH2);  2.13 (td, 3J(H, H) = 8.0, 3.2 Hz, 1H, 
1-CH); 2.02 (m, 1H, 5-CH); 1.52 (m, 1H, 6-CH).  
19F-NMR (377 MHz, CDСl3, rotamers): 96.54, 96.50 (2 d, 3J(F, H) = 
7.5 Hz, 3F, CHCF3); 87.54, 87.45 (2 t, 3J(F, H) = 7.5 Hz, 3F, 
OCH2CF3).  
IR (neat): 1758 (ν C=O in COOMe), 1741 (ν C=O in 
NCOOCH2CF3) cm-1.  
MS (m/z): 336 (M+1)+. 
Further elution gave the isomer 84b (240 mg, 0.88 mmol, 5%) as a yellowish oil. Rf 
= 0.4 in hexane/EtOAc = 5/1. 
1Н-NMR (400 MHz, CDСl3, rotamers): 4.53 (m, 1H, OCH2CF3); 4.43, 4.40 (2 d, 
3J(H, H) = 4.8 Hz, 1H, 2-CH); 4.30 (m, 1H, OCH2CF3); 3.81 (m, 
1H, 4-CH2); 3.77, 3.75 (2 s, 3H, OCH3); 3.69 (m, 1H, 4-CH2); 2.26 
(m, 1H, 1-CH); 2.07 (m, 1H, 5-CH); 2.20 (m, 1H, 6-CH). 
19F-NMR (377 MHz, CDСl3, rotamers): 96.02 (d, 3J(F, H) = 7.5 Hz, 
3F, CHCF3), 87.67, 87.57 (2 t, 3J(F, H) = 7.5 Hz, 3F, OCH2CF3).  
MS (m/z): 336 (M+1)+. 
 
(1R,2S,5S,6R)-6-(Trifluoromethyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic 
acid, 49а 
A solution of 84a (500 mg, 1.49 mmol) in aq. HBr (36%, 10 
ml) was refluxed for 6 h and evaporated. The black tarry residue was 
redissolved in H2O (~1 ml), neutralized with aq. NaOH (0.3M) to pH 
~9 and submitted to an ion exchange column chromatography 
(Dowex 50 × 400). Elution with water followed by aq. pyridine 
(10%) afforded 49a (145 mg, 0.75 mmol, 50%) first as a yellowish amorphous solid 
(116 mg, 0.60 mmоl, yield 40%, purity 90%). [α] 20D  = -23.3 (c = 0.167 mg/ml, 
MeOH). 
1Н-NMR (400 MHz, D2O): 4.32 (s, 1H, 2-CH); 3.69 (dd, 2,3J(H, H) = 12.0, 3.6 Hz, 
1H, 4-CH2); 3.53 (d, 2J(H, H) = 12.0, 1H, 4-CH2); 2.51 (dd, 1H, 3J(H, H) = 7.8, 3.6 
Hz, 1-CH); 2.35 (dt, 1H, 3J(H, H) = 7.8, 3.6 Hz, 5-CH); 1.81 (m, 1H, 6-CH). 
19F-NMR (377 MHz, CD3OD): 95.48 (d, 3J(H, F) = 3.8 Hz, CF3). 
IR (KBr): 1617 (νas COO-), 1386 (νs COO-) cm-1. 
MS (m/z): 196 (M+1)+. 
Second fraction (50 mg, 17%) was mixture of 49а and 85а. 
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(1R,2S,5S,6R)-3-[(9H-Fluoren-9-ylmethoxy)carbonyl]-6-(trifluoromethyl)-
3-azabicyclo [3.1.0]hexane-2-carboxylic acid, 89а 
A solution of Fmoc-Cl (73 mg, 0.28 mmоl) in dioxane (2 ml) 
was added dropwise over 15 min to a solution of 49a+85а (50 mg, 0.26 
mmоl) and Na2CO3 (100 mg) in dioxane-water (25 ml, 2/3) at 0 ºC (ice 
bath). After being stirred at this temperature for 30 min, the reaction 
was left overnight at room temperature. Water (50 ml) was added and 
the formed solution was extracted with Et2O (3 × 5 ml). Organic layer 
was discarded; water phase was acidified with aq. HCl to pH ~1 and extracted with 
EtOAc (3 × 10 ml). After drying over (MgSO4) the solution was evaporated to give 
oily residue which was purified by HPLC (column: Vydac C20, 4.6 × 250 mm). 10 
mg (0.02 mmоl, 9%). White solid. 
1Н-NMR (400 MHz, СDСl3, rotamers): 7.80 (pseudo t, 2H, 3J(H, H) = 8.5, 7.0 Hz); 
7.63 (m, 2H); 7.40 (pseudo t, 2H, J = 9.5, 9.0 Hz); 7.32 (m, 2H); 4.54-4.13 (m, 4H, 
CHСH2O + 2-CH); 3.71, 3.62 (2 m, 2H, 4-CH2); 2.46, 2.37 (2 m, 1H, 1-CH); 2.19 
(m, 1H, 5-CH); 1.93 (m, 1H, 6-CH). 
19F-NMR (377 MHz, CD3OD): 94.21, 94.21 (2 bs, CF3).  
MS (m/z): 420 (M+1)+. 
 
(1S,2S,5R,6S)-6-(Trifluoromethyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic 
acid, 49b 
Amino acid 49b was purified synthesized from 84b analogous to 49а. 
Yellowish amorphous solid (yield 50%). 
1Н-NMR (400 MHz, D2O): 4.28 (d, 3J(H, H) = 4.0 Hz, 1H, 2-CH); 
3.58 (d, 2J(H, H) = 12.0 Hz, 1H, 4-CH2); 3.53 (dd, 2,3J(H, H) = 12.0, 
4.0 Hz, 1H, 4-CH2); 2.50 (dt, 1H, 3J(H, H) = 7.8, 4.0 Hz, 1-CH); 2.25 
(dt, 1H, 3J(H, H) = 7.8, 4.0 Hz, 5-CH); 1.93 (m, 1H, 6-CH). 
19F-NMR (377 MHz, CD3OD): 95.49 (d, 3J(H, F) = 3.8 Hz, CF3). 
13C-NMR (126 MHz, CD3OD): 169.60 (s, COOH); 124.94 (q, 1J(C, F) = 270.4 Hz, 
CF3); 61.94 (s, 2-CH); 46.50 (s, 4-CH2); 22.79 (s, 1-CH); 19.57 (s, 5-CH); 19.03 (q, 
2J(C, F) = 36.5 Hz, 6-CH). 
IR (KBr): 1620 (νas COO-), 1391 (νs COO-) cm-1. 
MS (m/z): 196 (M+1)+. 
 
2-tert-Butyl 3-methyl (1S,3S,5R,6R)-6-(trifluoromethyl)-2-azabicyclo[3.1.0] 
hexane-2,3-dicarboxylate, 97а 
2-tert-Butyl 3-methyl (1S,3S,5S,6S)-6-(trifluoromethyl)-2-azabicyclo[3.1.0] 
hexane-2,3-dicarboxylate, 97b 
2-tert-Butyl 3-methyl (1S,3S,5S,6R)-6-(trifluoromethyl)-2-azabicyclo[3.1.0] 
hexane-2,3-dicarboxylate, 97c 
3-Methyl 2-(2,2,2-trifluoroethyl) (1S,3S,5S,6S)-6-(trifluoromethyl)-2-
azabicyclo[3.1.0]hexane-2,3-dicarboxylate, 98 
CF3CHN2 (obtained as described above) was gradually blown off by an inert 
gas from the generator flask and passed through a drying tube (MgSO4) into a vessel 
containing a stirring mixture of 93 (4.00 g, 17.62 mmol) and anhydrous CuCl (500 
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mg). The reaction was monitored by 1H-, 19F-NMR and HPLC. After the starting 
material had been disappeared, the trifluoromethyldiazomethane bubbling was 
immediately stopped. The reaction mixture was diluted with CH2Cl2, filtered, and 
evaporated. The oily residue was submitted to flash chromatography. Elution with 
hexane/EtOAc = 20/1 produced 97a (1.46 g, 4.75 mmol, 27%) first as a colorless 
viscous oil. Rf = 0.5 in hexane/EtОAc = 5/1. [α] 20D  = +11.2 (c = 0.67 mg/ml, MeOH). 
1Н-NMR (400 MHz, CDСl3, rotamers): 4.42 (2 dd, 3J(H, H) = 
11.6, 3.2 Hz, 1H, 3-CH); 3.78, 3.62 (2 dd, 3J(H, H) = 7.2, 1.6 
Hz, 1H, 1-CH); 3.72, 3.71 (2 s, OCH3); 2.64 (m, 1H, 4-CH2); 
2.23-2.08 (m, 2H, 4-CH2, 6-CH); 1.90 (m, 1H, 5-CH); 1.47, 
1.38 (2 s, 9H, C(CH3)3). 
19F-NMR (377 MHz, CDСl3, rotamers): 97.04, 96.73 (2 d, 3J(H, F) = 7.5 Hz, CF3). 
13C-NMR (126 MHz, CDСl3, rotamers): 173.65, 173.51 (2 s, COOCH3); 153.99, 
153.38 (2 s, NCO); 124.22 (2 q, 1J(C, F) = 270.4 Hz, CF3); 81.14, 81.03 (2 s, 
OC(CH3)3); 59.53, 59.20 (2 s, 3-CH); 52.50, 52.36 (2 s, OCH3); 39.72 (2 overlapped 
q, 3J(C, F) = 3.8 Hz, 1-CH), 30.82, 29.84 (2 s, CH2); 28.29, 28.20 (2 s, С(CH3)3); 
25.95 (2 overlapped q, 2J(C, F) = 36.5 Hz, 6-CH); 19.38-20.29 (2 overlapped q, 3J(C, 
F) = 3.8 Hz, 5-CH). 
IR (neat): 1744 (ν C=O in COOMe), 1711 (ν C=O in Boc) cm-1. 
MS (m/z): 210 (M-Boc+2)+ (the sample was prepared by dissolving 97a in TFA, 
therefore the Boc group was cleaved). 
Further elution afforded 97b (1.31 g, 4.23 mmol, 22 %) as a 
white solid. Crystallization from cyclohexane gave crystals 
suitable for an X-ray analysis. Rf = 0.4 in hexane/EtОAc = 5/1. 
M.p. = 86-87 °C. [α] 20D  = -135.2 (c = 0.55 mg/ml, MeOH).
 
1Н-NMR (400 MHz, CDСl3, rotamers): 4.03 (bs, 1H, 3-CH); 3.72 (bs, 4H, 1-CH + 
OCH3); 2.42 (m, 1H, 4-CH2); 2.32 (m, 1H, 4-CH2); 2.03 (bs, 1H, 5-CH); 1.47 (bs, 
10H, 6-CH+C(CH3)3). 
19F-NMR (377 MHz, CDСl3, rotamers): 96.96, 96.54 (2 bs, CF3). 
13C-NMR (126 MHz, CDСl3, rotamers): 171.78 (s, COOCH3); 154.91 (bs, NCO); 
124.01 (q, 1J(C, F) = 271.6 Hz, CF3); 81.27 (s, OC(CH3)3); 60.30 (s, 3-CH); 52.43 (s, 
OCH3); 39.72 (q, 3J(C, F) = 2.52  Hz, 1-CH); 31.34 (bs, CH2); 29.27 (bs, 6-CH); 
28.21 (s, С(CH3)3); 19.92 (s, 5-CH). 
IR (KBr): 1758 (ν C=O in COOMe), 1711 (ν C=O in Boc) cm-1. 
MS (m/z): 210 (M-Boc+2)+. 
The isomer 97c (0.93 g, 3.00 mmol, 17%) was eluted from the 
column immediately after 97b as a colorless viscous oil. Rf = 
0.35 in hexane/EtОAc = 5/1. 
1Н-NMR (400 MHz, CDСl3, rotamers): 4.38, 4.22 (2 dd, 3J(Н, 
Н) = 10.0, 4.4 Hz, 1H, 3-CH); 3.82 (m, 1H, 1-CH); 3.75, 3.74 (2 s, 3H, OCH3); 2.65 
(m, 1H, 4-CH2); 2.30 (m, 1H, 4-CH2); 2.07 (m, 1H, 5-CH); 1.58 (m, 1H, 6-CH); 1.47, 
1.45 (2 s, 9H, C(CH3)3). 
19F-NMR (377 MHz, СDСl3): 103.65 (d, 3J(H, F) = 7.5 Hz, CF3). 
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13C-NMR (126 MHz, СDСl3, rotamers): 172.60 (s, COOCH3); 154.57, 154.05 (2 s, 
NCO); 126.16 (2 q, 1J(C, F) = 275.4 Hz, CF3); 80.96, 80.91 (2 s, OC(CH3)3); 63.48, 
62.94 (2 q, 5J(H, F) = 1.3 Hz, 3-CH); 52.39, 52.21 (2 s, OCH3); 41.02, 40.92 (2 q, 
3J(C, F) = 1.3  Hz, 1-CH); 28.98, 27.88 (2 s, CH2); 28.17, 28.11 (2 s, С(CH3)3); 27.41 
(2 overlapped q, 2J(C, F) = 35.2  Hz, 6-CH); 21.26, 19.92 (2 q, 3J(C, F) = 1.3 Hz, 5-
CH). 
IR (neat): 1752 (ν C=O in COOMe), 1706 (ν C=O in Boc).  
MS (m/z): 210 (M-Boc+2)+.  
In a case the reaction was not stopped after the starting material 73 had been 
disappeared, a replacement of COOC(CH3)3-group into COOCH2CF3-group occurred. 
Compound 98 was isolated from the complex reaction mixture by flash column 
chromatography with the purity of ~80% (containing ~20% of 97b). Crystals of 98 
suitable for an X-ray structure analysis were obtained by crystallization from 
cyclohexane. Rf = 0.38 in hexane/EtОAc = 5/1. White solid. 
M.p. = 56-57 °C. 
1Н-NMR (400 MHz, CDСl3, rotamers): 4.48 (bs, 1H, 
OCH2CF3); 4.27 (bs, 1H, OCH2CF3); 4.08 (bs, 1H, 3-CH); 
3.81, 3.68 (2 bs, 1H, 1-CH); 3.62 (s, 3H, OCH3); 2.36 (bs, 1H, 4-CH2); 2.30 (bs, 1H, 
4-CH2); 1.99 (bs, 1H, 5-CH); 1.46 (bs, 1H, 6-CH). 
19F-NMR (377 MHz, CDСl3, rotamers): 96.53, 96.15 (2 bs, 3F, CHCF3), 87.36, 87.28 
(2 bs, 3F, OCH2CF3). 
13C-NMR (126 MHz, CDСl3, rotamers): 170.91 (s, COOCH3); 153.44, 152.97 (2 s, 
NCO); 123.62 (q, 1J(C, F) = 271.6 Hz, CF3); 122.80 (q, 1J(C, F) = 276.8 Hz, CF3), 
61.73 (q, 2J(C, F) = 37.8 Hz, OCH2CF3); 61.58, 60.83 (2 bs, 3-CH); 52.74 (s, OCH3); 
40.80, 39.75 (2 bs, 1-CH); 32.30, 31.19 (2 s, CH2); 30.25 (q, 2J(C, F) = 34.0 Hz, 6-
CH); 20.05, 20.64 (2 s, 5-CH). 
IR (KBr): 1752 (ν C=O in COOMe), 1731 (ν C=O in NCOOCH2CF3). 
MS (m/z): 336 (M+1)+. 
 
(1R,3S,5R,6R)-2-(tert-Butoxycarbonyl)-6-(trifluoromethyl)-2-azabicyclo 
[3.1.0]hexane-3-carboxylic acid, 99а 
An aqueous solution of NaOH (13.8 ml, 0.93M, 12.8 
mmol) was slowly added to a stirring solution of 97a (1.0 g, 
3.23 mmol) in MeOH (10 ml) and the resulting suspension was 
stirred for 2 h. The transparent solution was evaporated (to 
remove MeOH), redissolved in H2O (10 ml) and extracted with CH2Cl2 (2 × 3 ml). 
The organic layer was discarded; water phase was acidified to pH ~2 with aq. HCl 
and extracted again with CH2Cl2 (3 × 5 ml). After being dried (MgSO4), the solvent 
was evaporated to produce 99a (905 mg, 3.06 mmоl, 95%) as a white solid. M.p. = 
121-122 °C. 
1Н-NMR (400 MHz, CDCl3, rotamers): 8.13 (bs, 1H, COOH); 4.61, 4.34 (2 dd, 3J(Н, 
Н) = 11.2; 2.0 Hz, 1H, 3-CH); 3.88, 3.74 (2 dd, 3J(Н, Н) = 6.8; 1.2 Hz, 1H, 1-CH); 
2.81-2.61 (m, 1H, 4-CH2); 2.30-2.22 (2 dd, 2,3J(Н, Н) = 14.0; 2.4 Hz, 1H, 4-CH2); 
2.08 (bs, 1H, 5-CH); 1.98 (m, 1H, 6-CH); 1.49-1.41 (2 s, 9H, С(CH3)3).  
19F-NMR (377 MHz, CDCl3, rotamers): 96.81, 96.50 (2 d, 3J(H, F) = 7.5 Hz, CF3).  
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IR (KBr): 1752 (ν C=O in COOH), 1650 (ν C=O in Boc) cm-1.  
MS (m/z): 296 (M+1)+.  
 
(1S,3S,5S,6S)-2-(tert-Butoxycarbonyl)-6-(trifluoromethyl)-2-azabicyclo 
[3.1.0]hexane-3-carboxylic acid, 99b 
Amino acid 99b (95% yield) was obtained from 97b 
analogous to 99а. White solid. M.p. = 121-122 °C. 
1Н-NMR (400 MHz, CD3OD, rotamers): 4.10 (bs, 1H, 3-CH); 
3.76, 3.66 (2 bs, 1H, 1-CH); 2.55 (2 d, J = 9.6 Hz, 1H, 4- CH2); 
2.34 (m, 1H, 4- CH2); 2.11 (bs, 1H, 5-CH); 1.89 (m, 1H, 6-CH); 1.46, 1.44 (2 s, 9H, 
C(CH3)3). 
19F-NMR (377 MHz, CD3OD, rotamers): 95.87, 95.62 (2 bs, CF3). 
13C-NMR (101 MHz, CD3OD, rotamers): 173.56 (bs, COOH); 155.20, 154.78 (2 bs, 
NCO); 124.30 (q, 1J(C, F) = 270.6 Hz, CF3); 81.23, 80.65 (bs, OC(CH3)3); 60.22 (m, 
3-CH); 39.69 (s, 1-CH); 31.35, 30.77 (2 q, 3J(C, F) = 2.8  Hz, CH2); 27.95 (bs, 6-
CH); 26.97 (s, C(CH3)3); 19.49, 20.02 (2 bs, 5-CH). 
IR (KBr): 1756 (ν C=O in COOH), 1654 (ν C=O in Boc) cm-1. 
MS (m/z): 296 (M+1)+. 
 
(1S,3S,5S,6R)-2-(tert-Butoxycarbonyl)-6-(trifluoromethyl)-2-azabicyclo 
[3.1.0]hexane-3-carboxylic acid, 99c  
Amino acid 99c (95% yield) was obtained from 97c 
analogous to 99а. White solid. M.p. = 120-121 °C. 
1Н-NMR (400 MHz, CD3OD, rotamers): 4.20 (2 dd, 3J(H, H) = 
10.0, 3.6 Hz, 1H, 3-CH); 3.73 (m, 1H, 1-CH); 2.64 (q, 2J(H, H) 
= 10.0 Hz, 1H, 4-CH2); 2.35 (m, 1H, 4-CH2); 2.20 (m, 1H, 5-CH); 1.77 (m, 1H, 6-
CH); 1.47, 1.42 (2 s, 9H, C(CH3)3). 
19F-NMR (377 MHz, CD3OD, rotamers): 103.17, 103.09 (2 d, 3J(H, F) = 7.5 Hz, 
CF3). 
13C-NMR (101 MHz, CD3OD, rotamers): 173.73, 173.58 (2 s, COOCH3); 156.73, 
156.39 (2 s, NCO); 128.21 (q, 1J(C, F) = 272.9 Hz, CF3); 82.57, 82.27 (2 s, 
OC(CH3)3); 65.27, 65.05 (2 q, 5J(C, F) = 2.0  Hz, 3-CH); 42.24, 42.01 (2 q, 3J(C, F) = 
2.0  Hz, 1-CH); 30.03, 29.14 (2 s, CH2); 28.71, 28.62 (2 s, C(CH3)3); 22.31 (2 
overlapped q, 2J(C, F) = 34.2  Hz, 6-CH), 22.46, 21.17 (2 q, 3J(C, F) = 2.0 Hz, 5-CH). 
IR (KBr): 1720 (ν C=O in COOH), 1694 (ν C=O in Boc). 
MS (m/z): 296 (M+1)+. 
 
(1R,3S,5R,6R)-3-Carboxy-6-(trifluoromethyl)-2-azoniabicyclo[3.1.0] 
hexane trifluoroacetate, 97a*TFA 
99a (500 mg, 1.69 mmоl) was dissolved in 5 ml of 
TFA/CH2Cl2 (1/4), and the mixture was stirred for 2 h. 
Evaporation of the solvent afforded 97*TFA (523 mg, 1.69 
mmol, quant.) as a white solid. M.p. = 145-146 ºC. 
1Н-NMR (400 MHz, CD3OD): 4.68 (dd, 3J(H, H) = 10.8, 3.2 Hz, 1H, 3-CH), 3.82 
(dd, 3J(H, H) = 6.4, 2.0 Hz, 1H, 1-CH), 2.82 (m, 1H, 4-CH2), 2.53 (dd, 2,3J(H, H) = 
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14.0; 2.8 Hz, 1H, 4-CH2), 2.38 (dd, 3J(H, H) = 10.8; 5.6 Hz, 1H, 5-CH), 2.10 (m, 1H, 
6-CH). 
19F-NMR (377 MHz, CD3OD): 95.31 (d, 3J(H, F) = 3.8 Hz, CF3); 85.43 (s, 
CF3COO). 
13C-NMR (126 MHz, CD3OD): 171.12 (s, COOH); 161.15 (q, 2J(C, F) = 36.5 Hz, 
COOH in CF3COO-); 123.72 (q, 1J(C, F) = 270.4 Hz, CF3); 116.48 (q, 1J(C, F) = 
292.3 Hz, CF3 in CF3COO-); 59.85 (s, 3-CH); 38.17 (q, 3J(C, F) = 3.8 Hz, 1-CH); 
29.58 (s, CH2); 23.08 (q, 2J(C, F) = 36.5 Hz, 6-CH); 20.81 (q, 3J(C, F) = 3.8 Hz, 5-
CH).  
IR (KBr): 1730 (ν C=O in COOH), 1683 (νas COO-), 1632 (νs COO-). 
MS (m/z): 196 (M-CF3COO)+. 
 
(1S,3S,5S,6S)-3-Carboxy-6-(trifluoromethyl)-2-azoniabicyclo[3.1.0]hexane 
trifluoroacetate, 97b*TFA 
97b*TFA was synthesized from 99b analogous to 
97a*TFA (quant. yield). White solid. M.p. = 143-144 °C. 
[α] 20D  = -25.0 (c = 0.207 mg/ml, MeOH). 
1Н-NMR (400 MHz, CD3OD): 4.21 (t, 3J(Н, Н) = 8.0 Hz, 1H, 
3-CH); 3.75 (dd, 3J(Н, Н) = 6.0, 2.0 Hz, 1H, 1-CH); 2.66 (dd, 2,3J(Н, Н) = 12.8, 8.0 
Hz, 1H, 4-CH2); 2.56 (m, 1H, 4-CH2); 2.38 (m, 2H, 5-CH and 6-CH). 
19F-NMR (377 MHz, CD3OD): 104.13 (d, 3J(H, F) = 7.5 Hz, CF3CH); 85.37 (s, 
CF3COO-). 
13C-NMR (101 MHz, CD3OD): 169.71 (s, COOH); 161.15 (q, 2J(C, F) = 35.2 Hz, 
COO- in CF3COO-); 125.52 (q, 1J(C, F) = 270.9 Hz, CHCF3); 116.49 (q, 1J(C, F) = 
289.2 Hz, CF3 in CF3COO-); 58.06 (s, 3-CH), 37.67 (q, 3J(C, F) = 4.0 Hz, 1-CH); 
29.76 (s, 4-CH2), 21.22 (q, 2J(C, F) = 37.3 Hz, 6-CH); 20.53 (q, 3J(C, F) = 2.0 Hz, 5-
CH). 
IR (KBr): 1733 (ν C=O in COOH), 1679 (νas COO-), 1636 (νs COO-) cm-1. 
MS (m/z): 196 (M-CF3COO)+. 
 
(1S,3S,5S,6R)-3-Carboxy-6-(trifluoromethyl)-2-azobiabicyclo[3.1.0] 
hexane trifluoroacetate, 97c*TFA 
97c*TFA was synthesized from 99c analogous to 
97a*TFA (quant. yield). White solid. M.p. = 143-144 °C. 
1Н-NMR (400 MHz, CD3OD): 4.39 (t, 3J(Н, Н) = 8.8 Hz, 1H, 3-
CH); 3.76 (t, 3J(Н, Н) = 6.4 Hz, 1H, 1-CH); 2.69 (m, 2H, 4-CH2); 2.44 (m, 1H, 5-
CH); 2.21 (m, 1H, 6-CH). 
19F-NMR (377 MHz, CD3OD): 104.13 (d, 3J(H, F) = 7.5 Hz, CF3CH); 85.37 (s, 
CF3COO-). 
13C-NMR (101 MHz, CD3OD): 169.19 (s, COOH); 160.20 (q, 2J(C, F) = 36.2 Hz, 
COO- in CF3COO-); 125.54 (q, 1J(C, F) = 273.6 Hz, CHCF3); 116.00 (q, 1J(C, F) = 
292.6 Hz, CF3 in CF3COO-); 61.11 (q, 5J(C, F) = 4.0 Hz, 3-CH); 39.81 (q, 3J(C, F) = 
2.0 Hz, 1-CH); 27.24 (s, 4-CH2); 21.46 (q, 2J(C, F) = 39.2 Hz, 6-CH); 22.02 (q, 3J(C, 
F) = 2.0 Hz, 5-CH). 
IR (KBr): 1731 (ν C=O in COOH), 1680 (νas COO-), 1635 (νs COO-) cm-1. 
N
H
CF3
COOH
*TFA
N
H
CF3
COOH
*TFA
  
83
MS (m/z): 196 (M-CF3COO)+. 
 
(1R,3S,5R,6R)-6-(Trifluoromethyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic 
acid, 97a 
An aqueous solution of 97a*TFA was neutralized with 
aq. NaOH (0.3M) and submitted to an ion exchange 
chromatography (Dowex 50 × 400). Elution with water and then 
with aq. pyridine (10%) afforded 97a in quant. yield. White solid (yield 100%). M.p. 
> 200 °C. [α] 20D  = -37.0 (c = 0.544 mg/ml, H2O). 
1Н-NMR (400 MHz, D2O): 4.39 (dd, 3J(Н, Н) = 11.2, 2.8 Hz, 1H, 3-CH); 3.80 (dd, 
3J(Н, Н) = 6.8, 2.4 Hz, 1H, 3-CH); 2.72 (m, 1H, 4-CH2); 2.48 (dd, 2,3J(Н, Н) = 14.0, 
2.8 Hz, 1H, 4-CH); 2.38 (dd, 3J(Н, Н) = 10.8, 6.4 Hz, 1H, 5-CH); 2.05 (m, 1H, 6-
CH). 
19F-NMR (377 MHz, D2O): 95.81 (d, 3J(H, F) = 3.8 Hz, CF3). 
MS (m/z): 196 (M+1)+. 
IR (KBr): 1636 (νas COO-), 1569 (δ NH2+), 1388 (νs COO-) cm-1. 
Under the same purification conditions the isomers 97(b,c)*TFA decomposed, 
partially (97b*TFA) or completely (97c*TFA). 
 
(2S)-2-{[9H-Fluoren-9-ylmethoxy)carbonyl]amino}-2-[3-(trifluoromethyl) 
bicyclo[1.1.1]pent-1-yl]carboxylic acid, 101 
A solution of Fmoc-Cl (1.30 g, 5.01 mmоl) in dioxane (5 
ml) was added dropwise over 15 min to a solution of 20 (1.00 g, 
4.77 mmol) and Na2CO3 (2 g) in dioxane-water (50 ml, 2/3) at 0 
ºC. After being stirred at this temperature for 30 min, the 
reaction was left overnight at room temperature. Water (500 ml) was added and the 
formed mixture was extracted with Et2O (3 × 50 ml). The organic layer was 
discarded; water phase was acidified with aq. HCl to pH ~1 and extracted with 
EtOAc (3 × 50 ml). The organic phase was dried (MgSO4) and evaporated to give 
101 (1.87 g, 4.29 mmol, 90%) as a white solid. An analytically pure sample was 
obtained by crystallization from hexane-EtOAc mixture. M.p. = 203-204 °C. 
1Н-NMR (400 MHz, СD3OD, rotamers): 7.71 (d, 3J(H, H) = 7.6, 2H); 7.64, 7.57 (2 t, 
3J(Н, Н) = 6.8 Hz, 2H); 7.34 (t, 3J(Н, Н) = 7.6 Hz, 2H); 7.27 (t, 3J(H, H) = 7.2 Hz, 
2H); 4.50, 4.36 (2 m, 1H, OCH2CH); 4.37 (dd, J = 11.5, 6.5 Hz, 1H, OCH2CH); 4.30 
(s, 1H, CHCOOH); 4.20 (t, 3J(H, H) = 6.8 Hz, 1H, OCH2CH); 1.94, 1,89 (2 d, 2J(Н, 
Н) = 9.2 Hz, 6H, CH2); 1.68 (s, 1H, CООH). 
19F-NMR (377 MHz, СD3OD, rotamers): 87.95, 87.82 (2 s, СF3). 
13С-NMR (101 MHz, СD3OD, rotamers): 171.85(s, COOH); 157.73 (s, NCO); 
144.54, 144.34 (2 s, tert-C in Fmoc-group); 141.84 (s, tert-C in Fmoc-group); 127.49 
(s, CH); 126.80 (s, CH); 124.81, 124.73 (2 s, CH); 124.42 (q, 1J(C, F) = 215.2 Hz, 
CF3); 119.57 (s, CH); 67.96, 67.83 (2 s, OCH2CH); 59.34, 58.69 (2 s, CCOOH); 
39.79, 39.22 (2 s, OCH2CH); 30.46, 30.35 (2 s); 25.31, 24.76 (2 q, 2J(C, F) = 27.3 
Hz, СCF3); 19.35, 20.20 (2 s).  
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(1R,3S,5R,6R)-2-[(9H-Fluoren-9-ylmethoxy)carbonyl]-6-(trifluoromethyl)-
2-azabicyclo[3.1.0]hexane-3-carboxylic acid, 110 
110 was synthesized from 50а analogous to 101. White 
solid (80% yield). M.p. = 193-194 °C. 
1Н-NMR (500 MHz, CD3OD, rotamers): 7.82 (t 3J(H, H) = 8.0 
Hz, 2H); 7.69 (t, 3J(H, H) = 7.0 Hz, 1.2H); 7.61 (dd, 3J(H, H) = 
7.0, 3,5 Hz, 0.8 H); 7.42 (pseudo q, 3J(H, H) = 7.0 Hz, 2H); 7.33 (t, 3J(H, H) = 7.0 
Hz, 2H); 4.61-4.47 (2 overlapped dd, J = 8.5, 3.0 Hz, 1H, 3-CH); 4.51 (dd, J = 10.0, 
6.5 Hz, 0.6H); 4.38 (m, 2H); 4.19 (t, J = 6.5 Hz, 0.4H); 3.92, 3.82 (2 dd, 3J(H, H) = 
7.0, 1.5 Hz, 1H, 1-CH); 2.82 (m, 1H, 4-CH2); 2.27-2.07 (m, 3H, 4-CH2, 5-CH and 6-
CH). 
19F-NMR (377 MHz, CD3OD, rotamers): 96.61, 96.41 (2 bs, CF3). 
13C-NMR (125 MHz, CD3OD, rotamers): 174.65, 174.33 (2 s, COOH); 155.03, 
154.71 (2 s, NCO); 143.84, 143.77, 143.65, 143.56 (4 s, tert-C in Fmoc-group); 
141.26, 141.20, 141.10 (3 s, 2 tert-C in Fmoc-group); 127.49 (s, CH); 126.87, 126.81 
(2 s, CH); 124.82, 124.74 (2 s, CH); 124.42 (2 q, 1J(C, F) = 270.4 Hz, CF3); 119.58 
(s, CH); 67.98, 67.85 (2 s, OCH2); 59.36, 58.71 (2 s, 3-CH); 46.97, 46.86 (2 s, 
OCH2CH); 39.79, 39.22 (2 q, 3J(C, F) = 3.8 Hz, 1-CH); 30.48, 29.36 (2 s, 4-CH2); 
28.28, 24.87 (2 overlapped q, 2J(C, F) = 36.3  Hz, 6-CH); 19.36, 20.22 (2 s, 5-CH). 
MS (m/z): 420 (M+1)+. 
 
Cyclo-(Pro-Val-Orn-20-DPhe)2, 100 
100 was synthesized manually using standard Fmoc-protocol of SPPS. 2-
chlorotrityl resin. The synthesis was started from DPhe using 2-chlorotrityl resin. 
While incorporating Orn into the peptide sequence, side chain protected Fmoc-
(ivDde)Orn was used. Incorporation of natural amino acids: Fmoc-amino acid (4 eq) / 
TСTU (4 eq) / 6Cl-HOBt (4 eq) and DIEA (8 eq) for 2 h. Incorporation of 20: 101 (2 
eq) / TСTU (2 eq) / 6Cl-HOBt (2 eq) / DIEA (4 eq) for 2 h. The coupling efficiency 
was monitored by Kaiser test.236 Deprotection was carried out with 20% piperidine in 
DMF for 20 min. The peptides were cleaved from the resin at room temperature by 
treatment with a cocktail of TFA (95%), water (2.5%) and TIS (2.5%) for 4 h with 
occasional shaking. The resin was filtered off and washed with pure TFA twice. The 
combined filtrates were evaporated under a gentle stream of nitrogen. The formed 
oily residue was redissolved in H2O and lyophilized to produce liniar decapeptide 
103. To the solution of 103 in СH2Cl2 (~ 1mg/ml) activators (3 eq. PyBop, 3 eq. 6Cl-
HOBt in minimum DMF) were added and the mixture was stirred for 30 min. After 
addition of 6 eq. DIEA the mixture was leaved to stirr for 24 h. Evaporation of the 
solvent afforded the residue, which was partitioned in H2O-EtOAc mixture. After 
being dried (MgSO4) the organic phase was evaporated to obtain a colorless oil (104), 
which was dissolved in 20 ml 2% N2H4 in DMF and stirred for 2 h. Evaporation of 
the solvent gave the residue which was purified further by HPLC. Analytical RP-
HPLC was done on an Agilent 1100 HPLC device using Zorbax Eclipse® XDB-C8 
column (4.6 mm × 150 mm). Peptide was purified by semipreparative RP-HPLC 
(Jasco, Japan; 10 × 250 mm Vydac C18-column). The crude peptide was loaded on 
the column as 5 mg/ml solution in MeOH. 5 mM HCl was used as ion-pairing agent 
N
CF3
COOH
Fmoc
  
85
instead of conventional TFA. After the purification, the peptide was of > 95% purity 
according to analytical HPLC and it was stored as lyophilized powder at -40 oC until 
use. 
MALDI-TOF (m/z): 1297.7 [M+1]+, calculated 1296.5. 
 
CF3-labelled PGLa analogues, 106-109 
Peptides were synthesized automatically using standard Fmoc-protocol of 
SPPS. Rink-amide resin. While incorporating Lys or Ser into the peptide sequence, 
side chain protected Fmoc-(Boc)Lys and Fmoc-(tBu)Ser were used. Incorporation of 
natural amino acids: Fmoc-amino acid (4 eq) / TBTU (4 eq) / 6Cl-HOBt (4 eq) and 
DIEA (8 eq) for 2 h. Incorporation of 20: 101 (2 eq) / TВTU (2 eq) / 6Cl-HOBt (2 eq) 
/ DIEA (4 eq) for 2 h. Deprotection was carried out with 20% piperidine in DMF for 
20 min. The peptides were cleaved from the resin at room temperature by treatment 
with a cocktail of TFA (95%), water (2.5%) and TIS (2.5%) for 4 h with occasional 
shaking. The resin was filtered off and washed with pure TFA twice. The combined 
filtrates were evaporated under a gentle stream of nitrogen and the products were 
precipitated with cold diethyl ether. After centrifugation the supernatant (diethyl 
ether) was decanted. The solid precipitate was redissolved in H2O and lyophilized. 
Peptides were purified by semi-preparative RP-HPLC (Jasco, Japan; 10 × 250 mm 
Vydac C18-column). The crude peptides were loaded on the column as 7 mg/ml 
solution in MeOH. The H2O/MeCN gradients were individually optimized for each 
peptide at 30-40 °C. 5 mM HCl was used as ion-pairing agent instead of conventional 
TFA. After purification, all peptides were of > 95% purity according to analytical 
HPLC, and they were stored as lyophilized powders at -40 °C until use. 
106, MALDI-TOF (m/z): 2045.9 [M]+, calculated 2046.5. 
107, MALDI-TOF (m/z): 2088.3 [M]+, calculated 2088.6. 
108, MALDI-TOF (m/z): 2046.1 [M]+, calculated 2046.5. 
109, MALDI-TOF (m/z): 2088.2 [M]+, calculated 2088.6. 
 
SAP and its CF3-labelled analogues, 111-116 
All peptides (SAP and 111-116) have been synthesized manually using 
standard solid phase Fmoc-protocols. 2-Chlorotrityl resin. While incorporating Arg 
into the peptide sequence, side chain protected Fmoc-(Pbf)Arg was used. 
Incorporation of natural amino acids: Fmoc-amino acids (4 eq) / TBTU (4 eq) / 6-Cl-
HOBT (4 eq) and DIEA (8 eq) for 2 h. 51a was incorporated by utilizing 110 (2 eq) / 
DIC (6 eq) / 6-Cl-HOBt (2 eq) for 2 h. The incorporation of 20 was achieved by 
using 101 (2 eq) / TBTU (2 eq) / 6-Cl-HOBt / DIEA (4 eq) for 2 h. While 
incorporating 12-Pro (next to 51a), Val and Arg double couplings were used. Second 
couplings were done by using Fmoc-amino acid (4 eq) / PyBop (4 eq) / DIEA (8 eq). 
The coupling efficiency was monitored by Kaiser test. Deprotection was carried out 
with 20% piperidine in DMF for 20 min. The peptides were cleaved from the resin at 
room temperature by treatment with a cocktail of TFA (95%), water (2.5%) and TIS 
(2.5%) for 12 h with occasional shaking. The resin was filtered off and washed with 
pure TFA twice. The combined filtrates were evaporated under a gentle stream of 
nitrogen and the products were precipitated with cold diethyl ether. After 
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centrifugation the supernatant (diethyl ether) was decanted. The solid precipitate was 
redissolved in H2O and lyophilized. Analytical RP-HPLC was done on an Agilent 
1100 HPLC device using Zorbax Eclipse® XDB-C8 column (4.6 × 150 mm). Peptides 
were purified by preparative RP-HPLC (Jasco, Japan; 25 × 250 mm Vydac C20-
column). The H2O/MeOH gradients were individually optimized for each peptide at 
40 °C. The crude peptides were loaded on the column as 50 mg/ml solution in 
MeOH. 5 mM HCl was used as ion-pairing agent instead of conventional TFA. 
After the purification, all peptides were of > 95% purity according to analytical 
HPLC and they were stored as lyophilized powders at -40 oC until use. 
SAP, MALDI-TOF (m/z): 1998. 7 [M+1]+, calculated 1997.5. 
111, MALDI-TOF (m/z): 2076.4 [M+1]+, calculated 2075.5. 
112, MALDI-TOF (m/z): 2089.7 [M]+, calculated 2089.5. 
113, MALDI-TOF (m/z): 2075.9 [M]+, calculated 2075.5. 
114, MALDI-TOF (m/z): 2077.7 [M]+, calculated 2077.5. 
115, MALDI-TOF (m/z): 2090.8 [M+1]+, calculated 2089.5. 
116, MALDI-TOF (m/z): 2089.5 [M]+, calculated 2089.5. 
 
Preparation of macroscopically aligned NMR samples 
Oriented samples of system peptide/lipid were prepared according to standard 
procedures described in details in recent reviews.58,65,237 
 
NMR Spectroscopy 
All solid state NMR measurements were carried out on a Bruker Avance 500 
MHz spectrometer (Bruker BioSpin, Rheinstetten, Germany). 19F-NMR was 
performed at 470 MHz with a 19F/1H double-tuned, flat-coil probe (Doty Scientific, 
Columbia, SC, USA) that could be manually tilted. Simple 1-pulse experiments with 
a 90° pulse width of 1.8 µs and 10-15 kHz TPPM 1H-decoupling were used to 
acquire regular 19F-NMR spectra. All samples were measured with the membrane 
normal parallel to the magnetic field. 
 
Calculation of PGLa and SAP structures 
The homonuclear 19F-19F dipolar couplings of 19F-NMR label 20 in five 
different positions of SAP and four positions of PGLa were collected and used to 
calculate the orientation of the peptides in the lipid bilayer. The backbone of SAP 
was modeled as an ideal α-, 310-, π-helixes and PP II; the PGLa - as α-helix. The 
alignment of such ideal model structures in the lipid bilayer are described by a tilt 
angle τ with respect to the membrane normal and by an azimuthal rotation ρ around 
the helix axis. To determine these two values together with the order parameter Smol, 
all three parameters were systematically varied in a grid search. The minimal RMSD-
values (root mean square deviation between the experimental and calculated 19F-19F 
dipolar couplings) found were taken as a basis for ρ, τ and Smol. The method is 
described in detail in a number of recent reviews58,65,238 
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PART 7. 
SUMMARY 
 
A new trifluoromethyl-substituted conformationally rigid L-α-amino acid ((S)-
3-trifluoromethyl-bicyclopent-[1.1.1]-1-ylglycine, CF3-Bpg) was synthesized. This 
compound was specifically designed to serve as a proper 19F-label for substituting 
natural non-polar amino acids (Ala, Val, Leu, Ile, Met) in peptides, in order to study 
them by solid state 19F-NMR. The stereochemistry of the final product was 
determined by X-ray analysis, and its optical purity was confirmed using a lanthanide 
shift reagent. With the aim of scaling up the synthetic protocol, separation conditions 
of two key intermediates by crystallization were found. Thus, the scale of the 
synthesis could be successfully increased from milligrams to hundred grams.  
The new 19F-label CF3-Bpg was incorporated into the two antimicrobial 
peptides GS and PGLa, which are well structurally and functionally characterized, in 
order to demonstrate its compatibility with structural peptide studies by solid state 
19F-NMR. Four analogues of PGLa and one GS analogue were synthesized. The 19F-
labelled peptides were thoroughly analyzed by means of CD, solid state 19F-NMR, 
and antimicrobial tests. The new amino acid was shown to fully meet all 
requirements to serve as an ideal structural 19F-NMR label. 
As a basis for the design of further labels, a method for the construction of 
trifluoromethyl-substituted cyclopropane derivatives from alkenes and 
trifluoromethyldiazomethane was developed. The key feature of this transformation 
was the use of metallocatalysis. By using a modified Gaspar-Roth procedure, the 
optimized synthetic scheme allowed to obtain the target compounds on a gram scale. 
Proline and norcoronamic acid were used as examples to demonstrate the 
applicability of this strategy for synthesizing trifluoromethyl-substituted analogues of 
natural amino acids, being a fundamentally new approach for constructing of 
compounds of this class. 
Using this approach a library of new 19F-labels, trifluoromethyl-substituted 
conformationally restricted L-α-amino acids, was thus designed to replace proline in 
peptides. All compounds, except for 2-(trifluoromethyl)-proline, were successfully 
synthesized. The stereoconfiguration of the different isomeric products was 
established by NMR and X-ray structural analysis. One isomer among the five 
synthesized, namely (1R,3S,5R,6R)-6-(trifluoromethyl)-2-azabicyclo[3.1.0]hexane-3-
carboxylic acid (CF3-MePro) was used for further studies.  
The new 19F-labels CF3-Bpg and CF3-MePro were incorporated into a novel 
cell-penetrating peptide SAP and six 19F-labelled analogues were synthesized. Their 
conformational behaviour was investigated, showing that the label CF3-MePro 
stabilizes the helical PP II conformation of SAP, while CF3-Bpg has no influence. 
The structure, dynamics and orientation of SAP in lipid membranes were then studied 
by solid state 19F-NMR, showing that the peptide prefers a surface-bound PP II helix 
under certain conditions. 
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ZUSAMMENFASSUNG 
 
Eine neue Fluor-markierte konformationell starre L-α-Aminosäure ((S)-3-
Trifluoromethyl-bicyclopent-[1.1.1]-1-ylglycine, CF3-Bpg) wurde synthetisiert. Diese 
Verbindung wurde als eine ideale Markierung für die Substitution von in der Natur 
vorkommenden, unpolaren Aminosäuren (Ala, Val, Leu, Ile, Met) in Peptiden 
konzipiert, um sie für Festkörper 19F-NMR Untersuchungen einzusetzen. Die 
Stereokonfiguration des Produkts wurde mittels Röntgenbeugungsanalyse ermittelt, 
und die optische Reinheit wurde mit Hilfe von „Lanthanide-shift“ Reagenzien 
bestätigt. Um die Synthese zu optimieren, wurden Bedingungen für die Trennung von 
zwei Schlüsselintermediaten durch Kristallisation gefunden. Damit lieβ sich der 
synthetische Maßstab erfolgreich von einigen Milligramm auf ca. hundert Gramm 
erhöhen.  
Die neue 19F-Markierung CF3-Bpg wurde in die antimikrobiellen Peptide GS 
und PGLa eingebaut, die strukturell und funktionell bereits gut untersucht worden 
sind. Vier PGLa-Analoga und ein GS-Analog wurden synthetisiert. Diese 19F-
markierten Peptide wurden umfassend mittels CD, Festkörper 19F-NMR und 
antimikrobiellen Tests charakterisiert. Es konnte gezeigt werden, dass CF3-Bpg alle 
Voraussetzungen einer idealen strukturellen 19F-Markierung erfüllt. 
Als Grundlage zur Darstellung weiterer 19F-Markierungen wurde eine neue 
Methode für die Herstellung von Trifluormethyl-substituierten Cyclopropan-
Derivaten aus Alkenen und trifluormethyldiazomethan entwickelt. Der Schlüssel zum 
Erfolg dieser Transformation war die Anwendung einer Metallkatalyse. Mit Hilfe 
einer optimierten Gaspar-Roth Methode wurden die gewünschten Produkte im 
Gramm-Maβstab synthetisiert. Am Beispiel von Prolin und Norkoronamin-Säure 
wurde gezeigt, dass sich diese neue Strategie für die Synthese der Trifluormethyl-
substituierten Analoga von natürlichen Aminosäuren eignet. 
Auf diese Weise wurde eine Bibliothek mit neuen 19F-Markierungen, 
bestehend aus Trifluormethyl-substituierten konformationell beschränkten L-α-
Aminosäuren, für die Substitution von Prolin in Peptiden entworfen. Alle 
Verbindungen, außer 2-(Trifluormethyl)-prolin, wurden erfolgreich synthetisiert. Die 
Stereokonfiguration der hergestellten, isomeren Aminosäuren wurde mit Hilfe von 
NMR und Röntgenbeugungsanalyse bestimmt. Eines der sechs synthetisierten 
Isomere, (1R,3S,5R,6R)-6-(Trifluromethyl)-2-azabicyclo[3.1.0]hexan-3-carbonsäure 
(CF3-MePro), wurde für die weiteren Untersuchungen ausgewählt.  
Die neuen 19F-Markierungen CF3-Bpg und CF3-MePro wurden in das neue 
Zell-penetrierende Peptid SAP eingebaut, und fünf Fluor-markierte Analoga wurden 
synthetisiert. Das konformationelle Verhalten aller Peptide wurde untersucht. Es 
konnte gezeigt werden, dass die Aminosäure CF3-MePro die PP II-Konformation von 
SAP stabiliziert, während die Markierung CF3-Bpg sie hingegen nicht beeinflusste. 
Die Struktur, Dynamik und Orientierung von SAP in Lipidmembranen wurden 
mittels Festkörper 19F-NMR analysiert und zeigte, dass das Peptid unter bestimmten 
Bedingungen eine oberflächlich gebundene PP II Helix ausbildet. 
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ABBREVIATIONS 
 
acac acetylacetonate 
Aib aminoisobutyric acid 
AMPs antimicrobial peptides 
B0 static magnetic field 
9-BBN 9-borabicyclo[3.3.1]nonane 
Boc tert-butyloxy-carbonyl 
b.p. boiling point 
bs broad singlet 
СD circular dichroism 
CF3-MePro trifluoromethyl-4,5-methanoproline 
CF3-Bpg 3-trifluoromethyl-bicyclopent[1.1.1]-1-ylglycine 
4CF3-Phg 4-trifluoromethyl-phenylglycine 
6Cl-HOBt 6-chloro-N-hydroxybenzotriazole 
CPPs cell-penetrating peptides 
CSA chemical shift anisotropy 
d doublet 
DBU 1,8-diazobicyclo[5,4,0]undec-7-ene 
DCM dichloromethane 
DIC diisopropylcarbodiimide 
DIEA diisopropylamine 
DMF dimethylformamide 
DMPC 1,2-dimyristoyl-glycero-3-phosphocholine 
DMPG 1,2-dimyristoyl-glycero-3-phospho-1-glycerol 
Dowex-50 cation-exchanging resin 
EI electronic ionization 
EM electron microscopy  
F3-Aib 2,2,2-trifluoro-aminoisobutyric acid 
4F-Phg 4-fluoro-phenylglycine 
FA fluorine-labelled amino acid 
Fmoc 9-fluorenylmethoxy-carbonyl 
GC gas chromatography 
GC-MS gas chromatography with mass detection 
GS gramicidin S (antimicrobial peptide)  
HCTU 5-chloro-1-[bis(dimethylamino)methylene]-1H-
benzotriazolium 3-oxide hexafluorophosphate 
HPLC high performance liquid chromatography 
IR  infrared (spectroscopy) 
ivDde 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylilide)-3-
methylbutyl 
LSR lantanoid shifting reagent 
m multiplet 
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MALDI-TOF matrix assisted laser-induced desorption/ionization with 
time-of-flight detection 
MIC minimal inhibitory concentration 
m.p. melting point 
NMR nuclear magnetic resonance 
P/L peptide/lipid 
PGLa peptidyl-glycylleucine-carboxyamide (antimicrobial 
peptide) 
Pbf 2,3,4,6,7-pentamethyldihydro-benzofuran-5-sulfonyl 
PP I poly-L-proline helix of the type 1 
PP II poly-L-proline helix of the type 2 
PyBop (benzotriazol-1-yloxy)tripyrrolidino-phosphonium 
hexafluorophosphate 
PPTS pyridine p-toluene sulfonate 
PTSA p-toluene sulfonic acid 
RMSD root mean square deviation 
ppm  parts per million 
PRPs proline rich peptides 
q quartet 
py pyridine 
s singlet 
SAP Sweet Arrow Peptide (cell-penetrating peptide) 
SPPS solid phase peptide synthesis 
t triplet 
TLC thin layer chromatography 
TIS triisopropylsilane 
TBTU O-benzotriazol-1-yl-N,N,N',N'-tetramethyl-uronium 
tetrafluoroborate 
TFA trifluoroacetic acid 
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